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“Science, my lad, is made up of mistakes, but they are mistakes which it is useful to
make, because they lead little by little to the truth.”
Jules Verne, A Journey to the Center of the Earth
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Abstract




In this thesis, we develop statistical methodology to find solutions to contemporary
problems in renal research. These problems include 1) assessing the association of the
underlying kidney function and the risk of survival events, 2) early detection of progres-
sion towards renal failure amongst primary care patients, and 3) long-term influences
of acute kidney injury occurrences on the subsequent kidney function. Joint modelling
of longitudinal and time-to-event outcome and Cox model with time-varying covari-
ate are considered to answer the first problem. Whilst parameters are estimated by
maximum likelihood (ML) using an expectation-maximisation (EM) algorithm for the
former model, by partial likelihood for the latter. Results show that Cox model un-
derestimates the association parameter between the longitudinal and survival processes,
and joint models correct this. A longitudinal model with a non-stationary stochastic
process is developed for the second problem. Parameters are estimated by ML using a
Fisher-Scoring algorithm. Based on the results of this model, we obtain the predictive
distribution of meeting the clinical guideline for detecting progression. Results show that
there are patients with very high probability and emerging behaviour of progression. By
these probabilities, we aim to inform clinical decision-making. Another longitudinal
model with a class of stationary stochastic processes and heavy tailed response distri-
bution is developed for the third problem. Parameters are estimated by ML using an
EM algorithm, and random effects are predicted using the conditional distribution of
random effects given data. Results show that AKI might have serious impacts on kidney
function such that on average the loss of kidney function doubles after having an AKI.
Nonetheless, there are substantial between patient heterogeneity in terms of this influ-
ence. The R package lmenssp which enables inference for a range of mixed models with
non-stationary stochastic processes is developed and its core features are presented.
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1.1 Longitudinal data analysis
Longitudinal data comprise repeatedly collected data on each study subject (e.g. pa-
tients). At each of the data collection times, information on a number of variables is
collected, e.g. date of the follow-up, serum creatinine, blood pressure etc., which we
call time-varying variables. However, some of the variables are collected only at study
entry, e.g. gender, called time-independent variables. The data collection times might
be pre-specified, e.g. in clinical trials, or might not be pre-specified, e.g. in observational
studies. Here, the latter might impose further aspects of data analysis as the observa-
tion times might depend on the phenomenon of interest. Repeated measurements on
the same subjects are typically dependent, whereas measurements on different subjects
are typically independent. The dependency amongst repeated measures makes longitu-
dinal data analysis a special statistical research area and requires development of novel
statistical methods, both exploratory and confirmatory, and new statistical software.
The random effects modelling framework (also known as mixed effects models) gives a
very useful and widely used data-analytic class for longitudinal data analysis. In these
models, whilst the relationships between the explanatory variables are captured by re-
gression parameters (also known as fixed effects) as in classical multiple linear regression,
the dependencies amongst the repeated measurements are captured by subject-specific
random parameters. Here, the subject-specific parameters are typically assumed to be
drawn from a statistical distribution. The working assumption with random effects
models is that given the random effects the repeated measures are independent. Early
development of these models is attributed to the seminal paper of Laird and Ware
(1982). A useful special case of this framework is the well-known random intercept
and random slope model, especially for longitudinal data sets consisting of short series.
Diggle (1988) proposed a flexible approach to modelling the dependency amongst the
repeated measurements by including stationary Gaussian processes as serially correlated
random effects. This proposal is especially useful for longitudinal data sets with long
series. The author also proposed the use of the variogram as a diagnostic tool for the
shape of the correlation function of the repeated measurements. Taylor, Cumberland
and Sy (1994) considered the use of non-stationary stochastic processes. Jennrich and
Schluchter (1986) and Lindstrom and Bates (1988) presented parameter estimation by
maximum likelihood (ML) using numerical algorithms, e.g. Newton-Raphson methods
and the expectation-maximization (EM) algorithm (Dempster, Laird and Rubin, 1977).
Robinson (1991) discusses the prediction of the random effects by best linear unbiased
prediction. Book length materials of longitudinal data analysis include Verbeke and
Molenberghs (2000), Diggle et al. (2002), Fitzmaurice et al. (2009) and Fitzmaurice,
Laird and Ware (2011) amongst others. For the details of variogram, see Diggle et al.
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(2002) from a perspective of longitudinal data analysis and Diggle and Ribeiro (2007) for
a geostatistical data analysis perspective. For stochastic processes, the interested reader
is referred to Ross (1996). In continuous longitudinal data analysis, the distribution of
the repeated measurements is typically assumed to be multivariate normal. However,
in some real life examples, this assumption might not be appropriate, e.g. the under-
lying distribution might have heavier tails than the multivariate normal. Pinheiro, Liu
and Wu (2001) proposed random effects models for multivariate t distributed repeated
measures and algorithms for ML estimation via EM algorithms. Rosa, Padovani and
Gianola (2003) consider mixed models with a class of heavy tailed distributions from a
Bayesian perspective. Software for longitudinal data analysis is now widely available.
We specifically consider the R programming language (R Development Core Team, 2014)
which is an open-software platform. The nlme (Pinheiro et al., 2013) and lme4 (Bates
et al., 2013) packages facilitate fitting random effects models. Whilst both packages are
able to fit the Laird-Ware model, random effects models with stationary Gaussian pro-
cess can also be fitted by the former package. The procedures in both packages assume
multivariate normal distributions for the continuous repeated measures.
Whilst more details on longitudinal data analysis and stochastic process modelling can be
found in Chapters 3 and 4, heavy tailed extensions can be found in Chapter 4. Software
on mixed models with non-stationary stochastic processes can be found in Chapter 5.
1.2 Survival data analysis
Survival data comprise time to a certain event from a well-defined time origin. The event
might be a single (and possibly terminating) event, e.g. death, or recurrent events,
e.g. asthma attacks. A number of explanatory variables (both time dependent and
independent) are collected together with the time-to-event data. Time-to-event data are
greater than zero and typically follow a right-skewed statistical distribution. Scientific
interest is mostly on hazard and survival functions. However, what makes analysis of
survival data a special statistical research area is censoring, defined as not knowing the
exact time of the survival event. There are three types of censoring mechanisms: 1)
left, 2) interval, and 3) right-censoring. Interval censoring covers the other two and is
the subject-matter when the time to event is known to be between two time points. If
we set the lower time point to 0, what we obtain is left censoring. Similarly, if we set
the upper time point to infinity, we obtain right censoring. Amongst these censoring
mechanisms, the typical and most extensively studied censoring mechanism, also the
one we typically experience in renal medicine, is right-censoring. Right-censoring can be
better understood by the following explanation. Not all the study subjects experience
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the survival event and we do not know the time-to-event for the subjects who do not
experience the survival event, only that the time-to-event is greater than or equal to the
latest observed time. Analysis of survival data requires development of novel statistical
methods and software, as for analysis of longitudinal data.
Methods for survival data analysis started by comparing survival curves amongst groups,
with Kaplan-Meier survival curves and the log-rank test (Kaplan and Meier, 1958;
Kalbfleisch and Prentice, 2002). Incorporation of explanatory variables became avail-
able with the Cox proportional hazards model (Cox, 1972). This is a semiparametric
regression method, since the baseline hazard function, i.e. hazard for the patients with
all covariates taking 0, is left unspecified. Parameters are estimated by the partial likeli-
hood method, which was shown to have good properties, e.g. efficiency and consistency
(Cox, 1975). The Cox model accommodates only time-independent covariates and as-
sumes that the hazard ratio between covariate sub-groups through time is constant, i.e.
proportional hazards. The model was then extended to time-varying covariates based
on the counting process approach (Andersen and Gill, 1982). This allows models with
non-proportional hazards to be built. Random effects models for survival data (also
known as frailty models) are also available, e.g. see Vaida and Xu (2000). An interest-
ing recent review of methods for survival data analysis can be found in Oakes (2013).
Whilst the beginners of survival data analysis might refer to Kleinbaum and Klein (2012)
as a self learning text, for more advanced methods the interested reader is referred to
Kalbfleisch and Prentice (2002), Lawless (2003) and Lee and Wang (2003). For survival
data analysis with a stochastic processes point of view, one might refer to Andersen et
al. (1993) and Aalen, Borgan and Gjessing (2008). The survival package (Therneau,
2013) in R provides survival curve comparisons and fitting of a wide range of survival
models, including the Cox model, time-varying survival models and frailty models.
More details on survival data methods can be found in Chapter 2.
1.3 Simultaneous analysis of longitudinal and survival data:
joint modelling
In prospective studies, longitudinal and survival data are typically collected at the same
time. Simultaneous analysis of these two types of data is of scientific interest and drives
many studies. With such analysis, whilst the questions that are related to longitudinal
and survival processes can be answered, questions on the association between these
processes can also be answered, potentially making better use of the available data. For
example, in renal research, the medical area that motivates this thesis, the following
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three questions might be of scientific interest and can be simultaneously answered by
joint analysis: 1) how does the kidney function evolve through time and differ in terms
of explanatory variables, 2) how does the hazard for renal replacement therapy evolve
through time and differ in terms of explanatory variables, and 3) how is the hazard for
renal replacement therapy influenced by the underlying kidney function? Historically,
analyses of longitudinal and survival data evolved separately as two major areas of
medical statistics. The intersection of interests from these two areas has yielded a fresh,
popular and rapidly growing research area, called joint analysis of longitudinal and
survival data.
Both longitudinal and survival data processes are continuous time stochastic processes,
with the values of a variable (e.g. kidney function) in continuous time for the former,
the hazard for the survival event in continuous time for the latter. These are the under-
lying data generating mechanisms, but are unobserved in real life. What we observe in
real life are the imperfect measurements of the longitudinal process at intermittent and
possibly irregularly spaced time points, and time to a survival event which is possibly
subject to censoring. These make the joint analysis of longitudinal and survival data
challenging. Initial attempts to combine these areas started with accommodating lon-
gitudinal data as a time-varying covariate into the survival models (Andersen and Gill,
1982). However, this approach assumes that the covariate is measured perfectly and is
available at each event time. But it is now known that measurement error (Carroll et
al., 2006) in the longitudinal covariate biases the association parameter between these
data towards zero (Prentice, 1982). A one-step improvement to this approach is the
two-stage analysis of longitudinal and survival data (Tsiatis, DeGruttola and Wulfsohn,
1995). This includes modelling the longitudinal data first separately and obtaining the
error-removed predictions at the event times in the first step. Then, in the second
step these predicted values are considered as the time-varying covariates. Although un-
doubtedly this approach is an improvement, it is still not optimal and introduces bias,
especially on the association parameter for the relationship between the longitudinal
and survival processes (Sweeting and Thompson, 2011). Simultaneous analysis of these
data, via joint models, made it possible to overcome the drawbacks of the aforemen-
tioned methods. Early works that facilitated simultaneous modelling of longitudinal
and survival data are Berzuini and Larizza (1996), Faucett and Thomas (1996) with
a Bayesian paradigm, and Wulfsohn and Tsiatis (1997) with ML via EM algorithms.
These works combine the random effects for longitudinal data and proportional hazards
model for survival data; the latter may also be viewed as a time-varying frailty model.
Henderson, Diggle and Dobson (2000) proposed flexible parametrisation of the associa-
tion structure between the two processes and introduced the inclusion of the stationary
Gaussian processes as the serially correlated random effects. Parameters are estimated
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by ML estimation via EM algorithms. Guo and Carlin (2004) inspected the flexible
parametrisation of the association structure with a Bayesian perspective. Wang and
Taylor (2001) considered inclusion of non-stationary stochastic processes and estimated
the parameters with Bayesian methods. There are now many papers published on joint
modelling which have extended the aforementioned works by modifying either the lon-
gitudinal or survival sub-models. A parametric model for the survival part of the joint
model can be found in Diggle, Sousa and Chetwynd (2007). Up to date reviews and the
aforementioned extensions can be found in Sousa (2011), McCrink, Marshall and Cairns
(2013), Gould et al. (2015). A book length material solely devoted to joint modelling is
the book of Rizopoulos (2012). Individual chapters on joint modelling are Chapter 7 of
Ibrahim, Chen and Sinha (2001) and Chapter 8 of Wu (2009). Software for joint models
include the R packages JM (Rizopoulos, 2010) and joineR (Philipson et al., 2012) for ML
estimation, and JMbayes (Rizopoulos, 2014) for Bayesian methods.
More details on the methodology and software of joint models can be found in Chapter
2.
1.4 Renal function and two kidney diseases: a brief overview
1.4.1 Renal function
Kidneys are bean-shaped organs that constitute the upper part of the urinary system.
Their roles include filtering blood, i.e. removing waste products, and regulating blood
volume and pressure, amongst others (Field, Pollock and Harris, 2010). The glomerulus
is the kidney’s filtration unit. A single kidney includes about one million glomeruli. It is
accepted that glomerular filtration rate (GFR) is the best overall measure of kidney func-
tion/health (Stevens et al., 2006). Normal GFR values are expected to be approximately
130 ml/min/1.73m2 of body-surface area for a young man, and 120 ml/min/1.73m2 for
a young woman (depending on age and body size). GFR less than 60 ml/min/1.73m2
indicates chronic kidney disease (CKD), and GFR less than 15 ml/min/1.73m2 indicates
end-stage renal disease and preparation for renal replacement therapy (RRT), i.e. dialy-
sis or transplantation. Direct measurement of GFR is expensive and difficult in routine
clinical practice. Alternatively, estimated versions, called eGFR, are widely used. There
are many formulae to obtain eGFR which combine kidney function biomarkers, e.g.
serum creatinine (SCr), and demographic factors, e.g. gender, age and ethniticity, in a
deterministic manner. Two popular ones are the Modification of Diet in Renal Disease
(MDRD, Levey and others (1999)) and Chronic Kidney Disease Epidemiology Collabo-
ration (CKD-EPI, Levey and others (2009)). Here, kidney function biomarkers are easy
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to measure in a routine blood test, but are known to be subject to substantial measure-
ment error, which is also inherited into eGFR. These noisy variables are biochemicals
that are expected to be removed from the body by the kidneys, but their levels in blood
might also be associated with other factors. For example, SCr is a muscle breakdown
product, and heavy drinkers are known to lose muscle. Such a person might have a
higher level of SCr than expected, yet have a pair of well-functioning kidneys. Another
example is that some drugs are known to inhibit creatinine clearance, and might lead
to measuring higher levels of SCr in the tests (Stevens et al., 2006).
1.4.2 Two kidney diseases
Chronic Kidney Disease (CKD; El Nahas and Levin (2009); Levey and Coresh (2012);
Jha et al. (2013); Arici (2014)) is defined based on either the existence of kidney damage,
e.g. increased protein level in urine, or decreased kidney function, e.g. GFR < 60
mL/min/1.73m2, that continues for at least three months. The term CKD covers a wide
range of kidney diseases that affect the function and structure of the kidneys. It might
be detected during routine blood tests, and some treatments can slow the progression
towards renal failure. However, it is usually detected during the assessment of co-morbid
conditions at possibly advanced stages, because kidney disease can be asymptomatic for
many years. Most common causes are diabetes mellitus, cardiovascular diseases and
hypertension. The risk factors include old age, obesity and family history. Many CKD
patients lose their kidney function gradually and do not experience kidney failure in their
lifetime. However, for some patients the disease is aggressive and might result kidney
failure in a short term. CKD is now accepted to be a major public health problem with
approximate worldwide prevalence of 10%.
Acute Kidney Injury (AKI; Bellomo, Kellum and Ronco (2012); Lameire et al. (2013);
KDIGO (2012)) is defined as a sudden fall in the kidneys’ excretory function, typically
within a defined period of time, e.g. 48 hours. For example, if the SCr levels increase
between 1.5 and 2 fold within 48 hours, it is called a stage 1 AKI. It is mostly a reflec-
tion of a disease that might also affect the kidneys, e.g. chest infection or heart attack.
AKI is common and potentially catastrophic amongst seriously ill patients, e.g. patients
in intensive care units. Impacts of AKI range between slight loss of kidney function
without actual damage, to complete renal failure and even death. Approximately 2
million deaths worldwide are attributed to AKI (Murugan and Kellum, 2011). Typi-
cally, there is no specific treatment for AKI; treatment is only supportive. The focus is
mostly on identification and treatment of the primary disease that drives AKI. However,
some patients, e.g. with AKI due to vasculitis, are known to response to some specific
therapeutic treatment options. Temporary dialysis is another option for treating AKI.
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CKD and AKI are now accepted to be highly associated syndromes, such that it is occa-
sionally argued that the distinction between the two is artificial (Chawla and Kimmel,
2012; Chawla et al., 2014). History of AKI is a risk factor for developing CKD. AKI
might worsen the severity of an existing CKD, and CKD patients are known to be at
high risk of experiencing an AKI.
More details on CKD and AKI can be found in Chapter 4.
1.5 Motivating cohort studies
1.5.1 Salford primary care cohort
This is a cohort study in Salford, Greater Manchester, UK, on patients who do not have
any kidney diseases, but are at high risk of developing such a disease. These patients
are identified as having predisposing conditions for renal diseases, e.g. having diabetes
mellitus, hypertension, cardiovascular diseases etc. The main aim of this study is to
detect any progression towards kidney disease at an early stage. Any patient who meets
the above criteria can enter the study whilst it is running. There is no rigid follow-
up schedule for the blood sample collections. Whilst on some occasions the timings of
the follow-ups are based on physicians’ decisions, in others the patients decide when
to go to the hospital, e.g. when they feel sick. Therefore, the follow-up times are
typically irregularly spaced and the maximum number of repeated measures per patient
differs between patients. Recorded variables include demographic characteristics of the
patients, dates of follow-ups, bio-marker measurements, treatment and co-morbidity
history. Amongst these variables, whilst demographic variables are collected only once
at baseline, the others are collected at the subsequent follow-ups. In addition to these
variables, date of death is recorded if a patient dies, and the follow-up terminates. Date
of death is typically confirmed from UK Office of National Statistics. The minimum lag
between two successive measurements is a day in most cases. When there are multiple
blood measurements on the same day, we set the arithmetic average of the multiple data
as the data of that day. The data set we have covers the cohort between March 7, 1997
and March 22, 2007 with 22,910 patients and a total of 392,780 repeated measurements.
A refined version of the data set for a single patient is given in Table 1.1. This patient was
a male and 74.2 years old when he entered the study. He provided data at 7 subsequent
follow-ups, and died at the age of 75. More details of the data and the detailed statistical
analysis can be found in Chapter 3. A longitudinal data version of the Salford primary
care cohort study can be found at
http://biostatistics.oxfordjournals.org/content/early/2014/12/16/biostatistics.kxu053/suppl/DC1
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Table 1.1: A portion of the data from Salford primary care cohort for a single patient
with identification number (ID) 48700. Gender takes 1 for females, 0 for males; Age0
is age at baseline (in years); Age is age at measurement; Stime is age at death or data
lock (March 22, 2007); Death is an indicator variable: 0 = alive, 1 = died.
ID SCr eGFR Gender Age0 Age Stime Death
48700 106 59.204 0 74.196 74.196 75.039 1
48700 105 59.737 0 74.196 74.921 75.039 1
48700 101 62.475 0 74.196 74.927 75.039 1
48700 93 68.716 0 74.196 74.932 75.039 1
48700 96 66.243 0 74.196 74.938 75.039 1
48700 95 67.036 0 74.196 75.006 75.039 1
48700 109 57.197 0 74.196 75.036 75.039 1
48700 88 73.220 0 74.196 75.039 75.039 1
1.5.2 CRISIS cohort
Chronic Renal Insufficiency Standards Implementation Study (CRISIS, Eddington et
al., 2010; Hoefield et al., 2010) is an on-going cohort study on all-cause CKD. It is
run by the Salford Royal NHS Foundation Trust. Recruitment of the patients was
started on October 1, 2002. Patients with eGFR less than 60 ml/min/1.73m2 without
RRT are invited to attend the study, and those who have signed the consent form are
recruited. The main aims of the study are to understand the associated factors of CKD
and the time-course of the disease. The set of variables recorded is similar to that of
the Salford primary care cohort. Since CRISIS is a study on CKD patients, RRT is
another possibility as a survival event. Data are censored at RRT or death (whichever
comes first). Data have been collected annually by protocol. Our data set covers CRISIS
cohort from October 1, 2002 to July 30, 2012. There are 1,611 patients with a total of
3,154 follow-up measurements. We aim to investigate with this data set the time-course
of CKD and the association between kidney function and risk for survival events. More
details can be found in Chapter 2. We are also able to obtain the records between the
planned (annual) follow-ups for the patients in CRISIS through the electronic records
of Salford Royal Hospital. In this data set, we have records between November 15,
2000, and February 28, 2013. There are 2,289 patients with a total of 48,382 repeated
measurements. We aim to investigate with this data set the influences of AKI events on
long-term kidney function amongst patients with existing CKD. More details regarding
this data set can be found in Chapter 4.
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1.6 Aims, contributions and organisation
This thesis is motivated by real-life medical problems that arise in renal research. We
aim to develop novel statistical methods to provide solutions to such problems. The
statistical methods considered in the thesis currently cover methods for longitudinal
and survival data analysis. The thesis provides the following contributions:
• Chapter 2: we investigate the association between kidney function and risk of
having RRT in a case-study. We prepared an accessible tutorial on joint modelling
of longitudinal and survival data with detailed applications. R codes are also
provided.
• Chapter 3: our primary aim in this study is to flag primary care patients in terms
of referral to secondary care. This is an important problem, since progression
towards renal failure might be asymptomatic for many years. A linear mixed
effects model with a non-stationary stochastic process is developed.
• Chapter 4: we investigate the influence of AKI occurrences on long term kidney
health by statistical modelling. Such a study is important in terms of understand-
ing the natural history of kidney function after acute kidney injury occurrences.
To the best of our knowledge, this study is the first one that uses advanced statis-
tical modelling to inspect the aforementioned phenomenon. A linear mixed model
with stationary stochastic processes and a heavy tailed response distribution is
developed.
• Chapter 5: an R package, lmenssp, is developed for mixed effects models with
non-stationary stochastic processes. Details of the usage and applications are
provided.
Each chapter of this thesis can be read separately since they include their own intro-
duction, conclusion and discussion sections. Therefore we decided to keep the amount
of information and references short in this chapter. Some guidance to the readers is as
follows. Chapter 2 can be seen as a very detailed introduction to the thesis. R codes
regarding Chapters 2, 3 and 4 are provided at the end of each chapter. In Chapter 6,
we provide general discussions and mention future work.
We focus on analysis of continuous univariate longitudinal data and time to a non-
recurrent event from a confirmatory data analysis perspective, and mostly use available
exploratory data analysis methods. Therefore, in this chapter we have reviewed the
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literature on longitudinal continuous data and non-recurrent survival data with an em-
phasis on statistical modelling. The interested reader might refer to the books we cited
for the other aspects.
1.7 Role in the published/submitted works
The role of O¨zgu¨r Asar in the submitted/published papers presented in the Chapters 2,
3, 4 and 5 is as follows:
• Chapter 2: statistical analysis, preparation of the manuscript, and final version of
the paper.
• Chapter 3: statistical analysis and manuscript preparation revising and extending
an unpublished technical report by Peter J. Diggle and Ines Sousa, and final version
of the paper.
• Chapter 4: statistical analysis and preparation of the manuscript.
• Chapter 5: development of the R package and preparation of the manuscript.
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Chapter 2
Joint modelling of repeated
measurement and time-to-event
data: an introductory tutorial
This chapter is based on the following paper:
Asar O¨, Ritchie R, Kalra PA and Diggle PJ (2015). Joint modelling of repeated mea-
surement and time-to-event data: an introductory tutorial. International Journal of
Epidemiology, 44(1): 334–344.
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Abstract
Backgound: The term ‘joint modelling’ is used in the statistical literature to refer to
methods for simultaneously analysing longitudinal measurement outcomes, also called
repeated measurement data, and time-to-event outcomes, also called survival data. A
typical example from nephrology is a study in which the data from each participant
consist of repeated estimated glomerular filtration rate (eGFR) measurements and time
to initiation of renal replacement therapy (RRT). Joint models typically combine linear
mixed effects models for repeated measurements and Cox models for censored survival
outcomes. Our aim in this paper is to present an introductory tutorial on joint modelling
methods, with a case study in nephrology.
Methods: We describe the development of the joint modelling framework and compare
the results with those obtained by the more widely used approaches of conducting sepa-
rate analyses of the repeated measurements and survival times based on a linear mixed
effects model and a Cox model, respectively. Our case study concerns a data set from
the Chronic Renal Insufficiency Standards Implementation Study (CRISIS). We also
provide details of our open-source software implementation to allow others to replicate
and/or modify our analysis.
Results: The results for the conventional linear mixed effects model and the longitu-
dinal component of the joint models were found to be similar. However, there were
considerable differences between the results for the Cox model with time-varying covari-
ate and the time-to-event component of the joint model. For example, the relationship
between kidney function as measured by eGFR and the hazard for initiation of RRT
was significantly underestimated by the Cox model that treats eGFR as a time-varying
covariate, because the Cox model does not take measurement error in eGFR into account.
Conclusions: Joint models should be preferred for simultaneous analyses of repeated
measurement and survival data, especially when the former is measured with error and
the association between the underlying error-free measurement process and the hazard
for survival is of scientific interest.
Key words: Chronic kidney disease, cohort study, epidemiology, joint modelling of lon-
gitudinal and survival data, measurement error, medical statistics, statistical software
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Key Messages
• Longitudinal studies often include both repeated measurement and survival out-
comes. Common practice is to analyse these data separately. This is mostly due
to the lack of awareness of the available tools for simultaneous analysis.
• Measurement error in a time-varying covariate biases the estimate of the underlying
association with the hazard for survival towards zero. Joint modelling corrects this.
• Joint modelling of longitudinal and survival data is preferable to separate analyses,
both to make optimal use of the available information and to obtain unbiased
estimates of the model parameters.
• The availability of publicly available software to fit joint models and examples on
their use will encourage wider use of joint models.
2.1 Introduction
Prospective medical studies typically record a variety of covariates on each subject, some
fixed (e.g. gender), others time-varying (e.g. age), together with two fundamentally
different kinds of outcome: longitudinal data at a regular or irregular sequence of time-
points, also called repeated measurements (e.g. estimated glomerular filtration rate,
eGFR); and time-to-event outcomes, also called survival data [e.g. time to initiation of
renal replacement therapy (RRT)].
Repeated measurement and survival data require different statistical methods, and are
traditionally analysed separately. Typical properties of these data are: (i) repeated
measurement sequences are intermittently collected and subject to measurement error;
(ii) occurrence of the survival event terminates the underlying measurement process,
potentially in an informative manner; and (iii) the underlying measurement process
affects the hazard for survival. Together, these properties imply that separate analysis
of repeated measurement and survival outcomes is potentially inefficient, because it
does not fully exploit the dependence between the repeated measurement process and
the hazard for survival, and leads to biased estimation of the association between the
two, because it ignores measurement error.
For example, in nephrology it is important to understand the relationship between
changes in a patients renal function over time and the corresponding changes in their
survival prognosis; but neither the changes in renal function nor the hazard for RRT are
directly observable at all times. For this reason, we need to build a statistical model that
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relates these unobservable quantities to each other and to the observable data. These
data consist of the intermittently measured, error-prone and possibly informatively cen-
sored eGFR measurements and the observed, possibly censored, times to RRT for each
patient in the study.
Statistical methods for repeated measurement and survival data have generated exten-
sive, but largely separate, literatures. For book-length reviews, see for example Diggle
et al. (2002) or Fitzmaurice, Laird and Ware (2011) for the former, and Kalbfleisch and
Prentice (2002) or Kleinbaum and Klein (2012) for the latter.
Recently, simultaneous analysis of these two types of data has become possible through
the development of the so-called joint modelling methods: see, for example, Wulfsohn
and Tsiatis (1997), Henderson, Diggle and Dobson (2000), Diggle, Sousa and Chetwynd
(2007) and Rizopoulos (2012). Much of the early methodological work was stimulated by
problems arising in AIDS research (Tsiatis, DeGruttola and Wulfsohn, 1995; Wulfsohn
and Tsiatis, 1997). More recently, joint modelling methods have been adopted in other
areas of clinical research, including cancer (Ibrahim, Chu and Chen, 2010), cardiovascu-
lar disease (Andrinopoulou et al., 2012) and kidney transplantation studies (Garre et al.,
2008; Daher Abdi et al., 2013). However, joint modelling methods remain under-used,
and the absence of an accessible introduction in the epidemiological literature inhibits
their wider adoption. The aim of this paper is to provide an introductory tutorial on
joint modelling embedded in a specific application in nephrology and including an il-
lustration of open-source software for joint modelling that is available within the R (R
Development Core Team, 2013) computing environment.
The paper is organised as follows. We first provide details of the data set that we use
throughout the paper, and define the required statistical terminology. We then formulate
repeated measurement, survival and joint models for these data and discuss their basic
properties. We then use the models to investigate the effect of changes in kidney function
on the hazard for RRT, and discuss our findings. R scripts to reproduce our analyses
are provided in the online supplementary material (available as Supplementary data at
IJE online).
2.2 Materials and Methods
2.2.1 Patient population
Patients were selected from the Chronic Renal Insufficiency Standards Implementation
Study (CRISIS; Hoefield et al. (2010); Eddington et al. (2010)) run by Salford Royal
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NHS Foundation Trust (SRFT). CRISIS is an ongoing prospective observational study of
outcome in all-cause chronic kidney disease (CKD) that has continued to recruit patients
since 1 October 2002. Patient records are updated at annual nephrology follow-ups by
trained research nurses. Renal function is estimated using the four-variable MDRD






× age−0.203 × 0.742I(female) × 1.21I(black) (2.1)
where SCr denotes serum creatinine. In our analysis, we ignored the ethnicity term in
Equation 2.1, because most of the patients in the data set we analysed were Caucasian
(96.3%). Predefined study end-points are death (confirmed by the Office for National
Statistics) and initiation of RRT, defined as chronic haemodialysis, peritoneal dialysis
or transplantation. In this paper, we consider data collected until 30 July 2012 and
initiation of RRT as the survival outcome. There are 1611 patients with a total number
of 3154 follow-up measurements.
2.2.2 Explanation of statistical terms
Repeated measures are eGFR measurements belonging to the same patient but performed
at different times, here corresponding to hospital visits. Measurement times are the
follow-up times at each hospital visit, defined as the years elapsed between study entry
and hospital visits. Measurement error is the difference between the computed value of
eGFR and the true (isotopic) GFR. A time-constant or baseline covariate is one whose
value does not change over time, e.g. gender, whereas a time-varying covariate is one
whose value does change over time and is available at all times, e.g. age. Covariates
are to be regarded as inputs to a biomedical system, whereas outcome variables, here
repeated measurements of eGFR and time to initiation of RRT, are to be regarded as
outputs.
A survival outcome is the time, from a defined origin, at which an event of clinical
interest (e.g. initiation of RRT) occurs. Typically, survival times T , can be either
observed or censored, the latter meaning that observation of the subject in question is
terminated before the event of clinical interest occurs; hence the data tell us that T is
at least T0, but we do not know the exact value of T . In our example, patients who had
either died or were still alive but had not begun RRT by 30 July 2012 are censored for
initiation of RRT, and we know only that initiation of RRT happened, if at all, after 30
July 2012. Censoring is non-informative if it is statistically independent of the outcome
of interest, informative otherwise. In our example, censoring due to death could be



































Figure 2.1: Hypothetical longitudinal data for four patients with five follow-ups.
informative or non-informative, depending on the cause of death, whereas censoring at
the study end-date, 30 July 2012, is unambiguously non-informative.
Finally, a random effect is a patient-specific coefficient that represents between-patient
heterogeneity in an outcome variable that cannot be explained by measured covariates.
This is best understood through an example. Figure 2.1 shows hypothetical data on
eGFR measured annually over 5 years for four different patients. All four patients show
an approximately linear decrease in eGFR over time, but from clearly different initial
values. A simple mathematical representation of this might be:
Yij = Ai + β ∗ tij + Zij , (2.2)
where Yij is the j
th (j = 1, . . . , 5) measurement for subject i (i = 1, . . . , 4) at time tij
(tij = 1, . . . , 4) and Zij is the corresponding (random) measurement error. The slope, β
is the same for all patients whereas the values of Ai differ among patients. In treating
Ai as a random effect, we are assuming that its values are drawn from a statistical
distribution. If patients also differed in their rate of decrease in eGFR, we would replace
the fixed effect β by a random effect, Bi, again assumed to be drawn from a statistical
distribution. A useful way to think about random effects is as proxies for unmeasured
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Figure 2.2: The underlying mechanism of the longitudinal and survival processes.
Rectangles denote observed outcomes, ellipses unobserved quantities and arrows di-
rected statistical dependencies. The causal chain of interest runs from GFR to haz-
ard for RRT, whereas eGFR does not ‘cause’ RRT but is statistically related to RRT
through its dependence on the unobserved GFR.
covariates.
2.2.3 Rationale for joint modelling
The distinction between covariates and outcome variables is an operational one, in the
sense that the same biological construct may be regarded as an input or an output
in different studies. For example, in renal research we could envisage a study whose
primary objective was to investigate the relationship between blood pressure and the
hazard for end-stage renal failure. In that context, blood pressure would be an input,
and progression to end-stage renal failure an output. However, we could equally envisage
a study of the efficacy of an antihypertensive medication in which dose would be an input
and blood pressure an output. A second, more technical distinction is that in order to
obtain an unbiased estimate of the effect of a covariate on an outcome variable using
standard survival analysis methods, it is necessary that the covariate can be measured
at all times and without error (Carroll et al., 2006). Hence in the present context,
if our only objective was to understand the effect of renal function on the hazard for
initiation of RRT and we were able to monitor error-free GFR continuously over time,
we would treat GFR as a time-varying covariate and formulate a statistical model for a
patient’s hazard given their GFR history. But this is infeasible. We therefore need to
model eGFR measurements and time to initiation of RRT jointly in order to understand
the relationship between the underlying error-free GFR and the hazard for initiation of
RRT. This is shown schematically in Figure 2.2.
The two components of the resulting joint model, which we explain in detail in the next
section of the paper, are:
i. a linear mixed model for the time-course of eGFR;
ii. and a proportional hazards model for the time to initiation of RRT with time-
varying random effects.
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Both components of the joint model will include terms for measured covariates and
unmeasured, error-free GFR, which we treat as a time-varying, patient-specific random
effect, GFR(t). This framework, and in particular the linkage of the two components of
the joint model through a shared random effect, allow us to answer a range of questions
simultaneously according to the goals of each specific application. For example:
i. what is the typical pattern of progression in GFR, and how is this affected by
baseline or time-varying covariates;
ii. and how do changes in level of GFR affect survival prognosis?
2.2.4 Links between missing data mechanisms and joint modelling
The term ‘missing data’ refers to data that are intended to be observed, but are un-
observed for some reason (Little and Rubin, 2002; Molenberghs and Kenward, 2007;
Ibrahim and Molenberghs, 2009). This is a common occurrence in both longitudinal
and cross-sectional studies, either in the explanatory variables or the outcome variables
or both. Missing data in longitudinal studies can be either intermittent, i.e. a patient
might miss some of their hospital visits and return to the study later, or drop-out, i.e. a
patient might leave the study prematurely. Missing data can be: (i) missing completely
at random; (ii) missing at random; or (iii) missing not at random (MNAR). Details of
these mechanisms can be found in any material on missing data; see for example, Lit-
tle and Rubin (2002), Molenberghs and Kenward (2007) and Ibrahim and Molenberghs
(2009). There is a close link between drop-out and joint modelling in that drop-out time
can be considered as a survival outcome. An operational distinction is that, in the miss-
ing data literature, drop-out is typically inferred from a patient’s failure to present at
a scheduled follow-up time and treated as a discrete-time outcome whereas, in the joint
modelling literature, event-time of interest is either recorded exactly or right-censored
at the study end-time. The MNAR case is of particular interest in the present context,
because it implies that the drop-out time conveys information about the unobserved,
error-free longitudinal measurement process over and above that provided by the longi-
tudinal measurements that are observed before drop-out. An example of MNAR in the
context of nephrology would be a randomised clinical trial in which patients are likely
to drop out when they perceive a lack of benefit from the diet.
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2.3 Explanation of statistical methods
2.3.1 Repeated measurements
The most widely used class of models for repeated measurement data is the linear mixed
effects model (Laird and Ware, 1982). This is defined by:
Yij = Y
∗
i (tij) + Zij = Xijβ +WijBi + Zij . (2.3)
Here, Yij denotes the j
th eGFR measurement for the ith patient, a value which is typi-
cally measured with error, Y ∗i (t) denotes the true GFR level at time t, and Zij denotes
measurement error. A patient’s true GFR level can be decomposed into two components:
fixed effects Xijβ; and random effects, WijBi. The fixed effects represent the expected
behaviour of kidney function, averaged over all patients who share the same covariate
information; hence, Xij is a vector containing the values of covariates that relate to the
ith patient at the time of their jth eGFR measurement. The effects of changing the
values of the covariates are represented by the corresponding elements of the regression
parameter vector β. The random effects describe how patient-specific true GFR levels
deviate from their expected behaviour. Each Wij is a vector containing the values of
covariates that relate to the ith patient at the time of their jth eGFR measurement,
whereas Bi is analogous to β but, rather than taking a fixed unknown value, varies ran-
domly among patients. Typically the Bi are assumed to follow a zero mean multivariate
Normal distribution. There is no requirement for the same covariates to be included in
the fixed and random effect components of the model, but typically the latter is a subset
of the former. Both Xij and Wij can include time-constant and time-varying covariates.
Parameters are typically estimated by maximum or restricted maximum likelihood (ML
and REML, respectively), and the random effects Bi are predicted by their conditional
expectations given the data, so as to minimize mean square prediction error. ML is a
general method for estimating parameters in complex statistical models that is known to
have desirable theoretical properties (see for example, Pawitan (2001)). Many familiar
elementary statistical methods can be derived as special cases of ML or REML estima-
tions including, for example, t-tests, linear regression and generalized linear modelling.
Note that no survival information is considered in Equation 2.3.
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2.3.2 Survival times
The most widely used model for analysing survival data is the Cox proportional hazards
model (Cox, 1972). This is given by:
λi(t|Ki) = λ0(t) exp(Kiα). (2.4)
Here, λi(t|Ki) is the hazard for the ith patient to experience the event of interest, e.g.
initiation of RRT, at time t. It depends on time-constant covariates represented by the
elements of a vector of covariates Ki with associated regression parameters α, and a base-
line hazard function λ0(t) that represents the hazard for (possibly hypothetical) patients
all of whose covariates take the value zero. In most applications, the main interest is in
estimating α, which describes how the covariates affect the relative, rather than absolute,
hazard. An attractive feature of the Cox proportional hazards methodology is then that
it allows the baseline hazard to be left unspecified. If the baseline hazard is of interest,
it can be estimated non-parametrically, or modelled parametrically with a specified class
of lifetime distributions (Kalbfleisch and Prentice, 2002). A common choice for a para-
metric specification is the Weibull hazard, which follows a power law, λ0(t) = λ0kt
k−1
where λ0 > 0 and k > 0. Piecewise constant or regression spline function are popular
choices for λ0(t) if more flexible parametric modelling is required (Rizopoulos, 2012).
Estimates of α are typically obtained by maximizing the partial likelihood (Cox, 1972,
1975) in the Cox model, or by ML estimation in parametric models.
In principle, time-varying covariates can be added to the model given in Equation 2.4 by
making the elements of Ki functions of time, hence Ki(t); the resulting model is known
as the Cox model with time-varying covariate. However, this requires all time-varying
covariates to be measured continuously and without measurement error, which is only
feasible in special cases, for example where the elements of Ki(t) are functions of time
itself. Note however, that in the Cox model any function of time alone is absorbed into
the baseline hazard, λ0(t), and therefore cannot be estimated using the partial likelihood.
In some applications, continuous measurement of time-varying covariates is induced by
interpolating between actual measurements, but this is both an artificial device and also
takes no account of measurement error. A key advantage of joint modelling is its ability
to handle irregularly and imperfectly measured time-varying covariates correctly.
Inclusion of random effects in the model given in Equation 2.4 is comparatively straight-
forward. The simplest example takes the form:
λi(t|Ki) = λ0(t) exp(Kiα+Ai) (2.5)
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where the Ai are drawn from a statistical distribution. In the survival literature, the
quantity exp(Ai) is called the frailty of the i
th patient, and the distribution of the Ai is
scaled so that the average frailty is 1.
2.3.3 Joint modelling
A joint model for data on eGFR and time to initiation of RRT can now be defined by
the following two equations:
Yij = Y
∗
i (tij) + Zij = Xijβ +WijBi + Zij , (2.6)
λi(t|Ki, Y ∗i (t)) = λ0(t) exp(Kiγ1 + Y ∗i (t)γ2). (2.7)
Here, γ2 measures the relationship between the unmeasured, error-free GFR process,
Y ∗i (t), and the time to initiation of RRT. The fundamental feature of joint modelling
is that repeated measurement and survival data are modelled simultaneously. The al-
gorithm for estimating the parameters of the joint model given in Equations 2.6 and
2.7 also exploits the model assumptions to predict the values of Y ∗i (t) at all times t,
and thereby to estimate the associated regression parameter γ2 while making proper
allowance for the measurement error in the observed eGFR values. The model can be
extended to include particular features of the error-free GFR processes Y ∗i (t). For exam-
ple, rate of change in GFR can be added to Equation 2.7 as an additional term with its
own regression parameter, i.e. Y ∗′i (t)γ3. Other possible extensions include interactions
of kidney function with a set of baseline covariates; lagged or cumulative effect of kidney
function on the hazard for survival. Alternatively, only the random effect component of
the longitudinal sub-model might be included in the survival sub-model instead of the
current kidney function level, Y ∗i (t). For further details, see Chapter 5 of Rizopoulos
(2012) and Henderson, Diggle and Dobson (2000).
Parameters of joint models are typically estimated by maximizing the likelihood, and
random effects are predicted by their conditional expectations given all of the data. The
interpretations of the parameters of a joint model are the same as for their linear mixed
effects and Cox components.
The benefits of joint modelling are not cost free. The main disadvantages of joint mod-
elling are the increase in computational effort required to fit the models and the relative
scarcity of software to enable their routine use. The former is only a significant problem
when dealing with very large data sets, in particular data sets with large numbers of
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repeated measurements on each subject. The latter is being addressed by the develop-
ment of packages such as JM (Rizopoulos, 2010) and joineR (Philipson et al., 2012) that
run within the open-source R computing environment.
2.4 Framework for statistical analysis
Since some patients missed their annual data updates, there are intermittent missing
values in the data set, which we treated as missing at random. Each patient contributed
both repeated measurement and survival outcomes; the former are the repeated mea-
surements of kidney function as determined by eGFR, the latter are (possibly censored)
times to initiation of RRT. In our analysis, we treated death before initiation of RRT
as a right-censored event-time. Our analysis comprised three main steps: (i) separate
longitudinal analysis of repeated eGFR measurements; (ii) separate survival analysis of
time to initiation of RRT using the Cox model with eGFR treated as a time-varying
covariate by carrying forward each observed value of eGFR at a constant level until the
next observed value on the same patient; and (iii) joint analysis of the repeated eGFR
measurements and time to initiation of RRT. In the first step, we built a linear mixed
effects model with repeated eGFR data as the response variable, ignoring the poten-
tially informative nature of the censoring of each eGFR sequence by the occurrence of
the survival event. In the second step, we analysed RRT with observed repeated eGFR
measurements treated as a time-varying covariate. In the third step, we considered joint
analysis of repeated eGFR measurements and time to initiation of RRT with the current
(unobserved) value of GFR included in the survival submodel in addition to the baseline
covariates. We analysed log-transformed eGFR (Y = log(eGFR)) data throughout for
the following three reasons. First, this transformation leads to an approximately linear
relationship with age and approximately symmetrical scatter about the long-term trend.
Second, analyses of log(eGFR) and log-transformed creatinine would be equivalent when
the former is re-adjusted with age and gender (see Equation 2.1). Finally, using a log
transformation leads to an interpretation of the fitted model in terms of relative, rather
than absolute, change in eGFR, which relates more directly clinical guidelines for mon-
itoring changes in kidney function.
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2.5 Results
2.5.1 Study population
All of the log(eGFR) measurements are shown in Figure 2.3. Individual trajectories
for 10 patients randomly selected among those with at least three observations are
highlighted. Median age at recruitment was 67.2 years (IQR 55.6-74.9); 603 (37.4%) of
the patients were female; 1551 (96.3%) of the patients were Caucasian; 509 (31.6%) had
SRFT as the base hospital. Mean log(eGFR) at the first hospital visit was 3.4 (standard
deviation 0.5); and mean log(eGFR) at the last hospital visit was 3.3 (standard deviation
0.6). The log(eGFR) measurements at first and last visits are displayed in the upper and
lower panels of Figure 2.4, respectively. In total, 516 (32%) of the patients had diabetes
mellitus, 1086 (67.4%) were current or former smokers and 342 (21.2%) had a history
of coronary artery disease (defined as previous myocardial infarction and/or coronary
revascularization procedure). Median follow-up period was 3.9 years (IQR 2.2-5.6); 304
(19%) of the patients experienced initiation of RRT. The Kaplan-Meier survival plot for
RRT as the survival outcome is displayed in Figure 2.5.
2.5.2 Separate analysis
Details of the variables considered in the longitudinal model for log(eGFR) and in the
survival model are presented in Table 2.1. Note that we decompose age at measurement
into age at recruitment and time since recruitment (in years) in order to differentiate
between cross-sectional and longitudinal effects of age. To explain this distinction, con-
sider the following simple regression model, in which age0 denotes age on entry to the
study:
log(eGFR) = α+ β1 ∗ age0 + β2 ∗ (age− age0) + noise.
In this model, the parameters β1 and β2 represent the cross-sectional and longitudinal
effects of age, respectively. If β1 = β2 the model reduces to:
log(eGFR) = α+ β1 ∗ age+ noise.
but there is no reason in general why this should be so. For example, if the stages
of the disease for different patients are approximately the same at each follow-up, the
cross-sectional effect β1 would be approximately zero; but as patients typically lose renal
function over time, the longitudinal effect β2 would be negative.







































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Figure 2.3: All log(eGFR) measurements. Trajectories for 10 randomly selected
patients are shown as connected line-segments.
2.5.3 Longitudinal model




i (tij) + Zij = Xijβ +Ai +Bitij + Zij , (2.8)
where tij denotes time since recruitment. The fixed effects estimates from the sepa-
rate longitudinal model for change in log(eGFR) are presented in Table 2.2. Kidney
function was found to decrease with increasing age at study start [Estimate = -0.005,
95% confidence interval (CI) -0.007, -0.003] and with increasing time under observation
(Estimate = -0.064, 95% CI -0.073, -0.056). Recall that parameter estimates represent
relative rather than absolute changes. Hence, a 1-year increase in age at study start was
associated with a relative decrease of 0.5% (=(exp(-0.005)-1)*100) in expected eGFR.
Similarly, a 1-year increase in time under observation was associated with a relative
decrease of 6.2% in expected eGFR. Patients living in the catchment area of SRFT were
found to have 15.1% higher expected eGFR at recruitment compared with the patients

































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Figure 2.4: log(eGFR) measurements at the first (left panel) and the last (right panel)
follow-ups.
Table 2.1: Covariates used in analyses of the CRISIS data.
Variable Explanation
Baseline age (Date at study start date at birth)/365.25
Follow-up Age at measurement age at baseline
Hospital base 1 if base hospital is SRFT, 0 otherwise
Gender 1 if male, 0 if female
Smoking 1 if ex or current smoker, 0 if never smoked
Alcohol 1 if alcohol consumer, 0 if abstinent from alcohol
Diabetes 1 if type I or type II diabetes, 0 if no diabetes
Co-morbidity 1 if having at least one of myocardial infarction,
coronary artery bypass surgery or stenting, 0 otherwise
initially managed at satellite units. Males were found to have 8.3% higher expected
eGFR than females. Patients who had type 1 or type 2 diabetes were found to have
9.2% lower expected eGFR than non-diabetic patients. No differences in expected eGFR
were found between ex or current smokers and non-smokers, between alcohol consumers
and abstainers from alcohol or between patients who did or did not have at least one
comorbidity event; respective p-values were 0.601, 0.098 and 0.468.
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Figure 2.5: Kaplan-Meier survival plot for RRT as the survival event.
Table 2.2: Estimated regression parameters, 95% confidence intervals (95% CI), stan-
dard errors (SE), p-values (p) and percentage relative effects (RE %) in separate lon-
gitudinal analysis of the CRISIS data set. The response variable is log transformed
eGFR. RE % corresponding to an estimate βˆ, expressed as expected percentage change
in eGFR, calculated as (exp(βˆ)− 1) ∗ 100.
Variable Estimate (95% CI) SE p RE %
Intercept 3.585 (3.463, 3.707) 0.062 <0.001 NA
Baseline age (years) -0.005 (-0.007, -0.003) 0.001 <0.001 -0.5
Follow-up (years) -0.064 (-0.073, -0.056) 0.004 <0.001 -6.2
Hospital base 0.141 (0.088, 0.194) 0.027 <0.001 +15.1
Gender 0.080 (0.028, 0.133) 0.027 0.003 +8.3
Smoking 0.014 (-0.040, 0.068) 0.028 0.601 +1.4
Alcohol 0.043 (-0.008, 0.093) 0.026 0.098 +4.4
Diabetes -0.097 (-0.151, -0.044) 0.027 <0.001 -9.2
Comorbidity -0.024 (-0.087, 0.040) 0.032 0.468 -2.4
2.5.4 Survival model
Results obtained from a Cox model for the survival outcome are displayed in Table 2.3.
Time-varying eGFR was associated with the hazard for RRT. The corresponding param-
eter estimate was -2.510 (95% CI -2.691, -2.330); hence, a 1% reduction in eGFR was
associated with a 2.5% (=exp(2.510/100)) increased risk of RRT, with lower and upper
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Table 2.3: Estimated regression parameters, 95% confidence intervals (95% CI), stan-
dard errors (SE), p-values (p), hazard ratios (HR) and related 95% confidence intervals,
in analysis of CRISIS data set with Cox model with time-varying covariate for RRT as
the event
Variable Estimate (95% CI) SE p HR (95% CI)
log(eGFR) -2.510 (-2.691, -2.330) 0.092 <0.001 0.081 (0.068, 0.097)
Baseline age (years) -0.030 (-0.038, -0.021) 0.004 <0.001 0.971 (0.963, 0.979)
Hospital base -0.368 (-0.645, -0.091) 0.141 0.009 0.692 (0.525, 0.913)
Gender 0.139 (-0.106, 0.385) 0.125 0.267 1.149 (0.899, 1.469)
Smoking 0.362 (0.112, 0.612) 0.128 0.005 1.436 (1.119, 1.844)
Alcohol 0.055 (-0.180, 0.290) 0.120 0.647 1.056 (0.835, 1.336)
Diabetes -0.109 (-0.366, 0.149) 0.131 0.409 0.897 (0.693, 1.161)
Comorbidity -0.043 (-0.403, 0.317) 0.184 0.815 0.958 (0.669, 1.373)
95% confidence interval limits of 2.4% (=exp(2.330/100)) and 2.7% (=exp(2.691/100)),
respectively. Baseline age was also associated with the hazard for RRT, but unexpect-
edly in the negative direction; the corresponding estimated hazard ratio per year of age
was 0.971 (95% CI 0.963, 0.979). Patients whose base hospital was not SRFT were
estimated to have 44.5% higher hazard for RRT than patients whose base hospital was
SRFT. Patients who were ex or current smokers were estimated to have a 43.6% higher
hazard for RRT than patients who never smoked. On the other hand, there were no
differences between males and females, between alcohol consumers and abstainers from
alcohol, between diabetic and non-diabetic patients or between patients who did or did
not have at least one comorbidity event; related p-values were 0.267, 0.647, 0.409 and
0.815, respectively.
2.5.5 Joint model
The longitudinal sub-model of the joint model was a random-intercept-and-random-slope
model, as given in Equation 2.8. Results are shown in Table 2.4. The results for the
longitudinal sub-model were consistent with the results from the separate longitudinal
analysis. This might be explained by the fact that the modelling assumptions are the
same and the censoring of the eGFR measurements due to RRT is not severe. The
differences in magnitudes of the parameter estimates were negligible and there was no
material difference in terms of statistical significance. In contrast, material differences
were found in the results for the survival processes. This shows the importance of
recognizing the measurement error in the observed values of eGFR. Hence, in what
follows we discuss only the results for the survival sub-models.
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Table 2.4: Results for joint modelling analysis of CRISIS data set. For the longitu-
dinal sub-model estimated parameters and related 95% confidence intervals (95% CI),
standard errors (SE), p-values (p) and precentage relative effects (RE %) are reported.
For the survival sub-model, estimated parameters, related 95% confidence intervals,
standard errors, p-values, hazard ratios (HR) and related 95% confidence intervals are
reported.
Longitudinal sub-model
Variable Estimate (95% CI) SE p RE %
Intercept 3.614 (3.495, 3.732) 0.060 <0.001 NA
Baseline age (years) -0.005 (-0.007, -0.003) 0.001 <0.001 -0.5
Follow-up (years) -0.073 (-0.081, -0.064) 0.004 <0.001 -7.0
Hospital base 0.133 (0.081, 0.185) 0.027 <0.001 +14.2
Gender 0.077 (0.026, 0.129) 0.026 0.003 +8.0
Smoking 0.021 (-0.032, 0.074) 0.027 0.430 +2.2
Alcohol 0.038 (-0.011, 0.088) 0.025 0.130 +3.9
Diabetes -0.096 (-0.149, -0.044) 0.027 <0.001 -9.2
Comorbidity -0.029 (-0.093, 0.035) 0.032 0.373 -2.8
Survival sub-model
Variable Estimate (95% CI) SE p HR (95% CI)
log(GFR) -3.656 (-4.042, -3.270) 0.197 <0.001 0.026 (0.018, 0.038)
Baseline age (years) -0.036 (-0.046, -0.026) 0.005 <0.001 0.964 (0.955, 0.974)
Hospital base -0.190 (-0.509, 0.128) 0.162 0.241 0.827 (0.601, 1.136)
Gender 0.204 (-0.085, 0.493) 0.148 0.167 1.226 (0.918, 1.637)
Smoking 0.480 (0.186, 0.774) 0.150 0.001 1.616 (1.204, 2.169)
Alcohol 0.036 (-0.239, 0.311) 0.140 0.796 1.037 (0.788, 1.365)
Diabetes 0.085 (-0.210, 0.380) 0.151 0.572 1.089 (0.811, 1.463)
Comorbidity -0.112 (-0.534, 0.310) 0.215 0.603 0.894 (0.586, 1.363)
Most importantly, we found that a 1% reduction in GFR level was associated with a
3.7% (95% CI 3.3%, 4.1%) increased hazard for RRT, compared with 2.7% (95% CI
2.4%, 2.9%) previously obtained in the separate analysis of the survival outcome. There
was no difference between patients whose base hospital was or was not SRFT (p-value =
0.241), whereas in the separate analysis of survival outcome, base hospital was associated
with the hazard for RRT (p-value = 0.009).
2.6 Discussion
Our aim in this paper has been to present an introductory tutorial on simultaneous anal-
ysis of repeated measurement and time-to-event outcome data, using the joint modelling
approach that features most prominently in the biostatistical literature. This approach
incorporates the most widely used methods that have been developed for separate anal-
ysis of the two types of outcome, namely linear mixed effects modelling and Cox propor-
tional hazards modelling with frailty, and combines the two by linking their respective
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random effects. The principal advantage of this approach over separate analyses of each
outcome is the correct treatment of noisy and incompletely observed time-varying co-
variate information, which enables unbiased estimation of the relationship between the
two.
We have reported an analysis of a data set from the CRISIS cohort on CKD patients,
where the repeated measurements are serial eGFR measurements and the survival out-
come is time to initiation of RRT. The results demonstrate the usefulness of kidney
function as a predictor for the hazard for initiation of RRT. This was substantially
underestimated in a separate analysis of time to initiation of RRT treating eGFR as a
time-varying covariate, because the separate analysis fails to take account of the measure-
ment error in eGFR. In general, measurement error in a covariate biases the estimate of
the associated regression parameter towards zero (Wulfsohn and Tsiatis, 1997; Ibrahim,
Chu and Chen, 2010; Prentice, 1982; Sweeting and Thompson, 2011).
We found an unexpected result that increased baseline age was associated with a de-
creased hazard for initiation of RRT. This is most likely explained by the fact that
regression associations do not generally equate to causal relationships. Another expla-
nation might be that younger patients with poor kidney function were given priority for
RRT.
Our analysis of time to initiation of RRT as the survival outcome alone, treating death
as a right-censored event time, could be criticised for failing to take account of the status
of RRT and death as asymmetrical competing risks, in the sense that RRT necessarily
precedes death, whereas death automatically censors initiation of RRT. Joint models
for such competing risks have been considered, for example in the work of Williamson
(2008), but are beyond the scope of this paper; see also Chapter 5.5 of Rizopoulos (2012).
Similarly, we did not include proteinurea or blood pressure data in our analyses because
both are subject to measurement error and are collected intermittently at irregular times.
We would argue that analysis of proteinurea and blood pressure together with eGFR
strictly requires multivariate joint modelling. This is an area of current methodological
research and cannot be implemented routinely in freely available software packages.
The joint modelling framework we considered in this paper is also called the shared
random effects model. An alternative approach to this formulation is the latent class
model. For a recent review, see Proust-Lima et al. (2014). Latent class models can be
fitted by the R package lcmm (Proust-Lima et al., 2014).
We have presented joint modelling results obtained by ML estimation. An alternative
approach for parameter estimation is Bayesian inference (Ibrahim, Chen and Sinha,
2001; Guo and Carlin, 2004). This can be applied to a limited class of models with
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the R package JMbayes (Rizopoulos, 2014). Model fit can be assessed by Akaike or
Bayesian Information Criteria (Zhang et al., 2014). The sensitivity of the fixed effects
parameters in the longitudinal sub-model might be investigated by, for example, index
of local sensitivity to nonignorability (Viviani, Rizopoulos and Alfo´, 2014). Diagnostic
tools can be applied to multiple-imputation based empirical residuals for the longitudinal
sub-model of the joint models (Rizopoulos, Verbeke and Molenberghs, 2010). Methods
to inspect the association between longitudinal and time-to-event data, to investigate
empirical residuals of the longitudinal sub-model after fitting a joint model and to detect
influential observations within the joint modelling framework can be found in Dobson
and Henderson (2003).
Software for the separate analysis of longitudinal and survival data is widely available.
For the results reported in this paper, we used the R packages nlme (Pinheiro et al., 2013)
and survival (Therneau, 2013) for longitudinal and survival data analysis, respectively.
Software for joint modelling is becoming increasingly available in statistical packages,
for example in the R packages JM (Rizopoulos, 2010), joineR (Philipson et al., 2012)
and JMbayes (Rizopoulos, 2014). The R scripts for the analyses reported in this paper
are provided as Supplementary data, available at IJE online.
2.7 Online supplementary material: R codes
We have two data sets, one for the longitudinal data and one for the survival data,
named as longitudinal.data and survival.data in R, respectively. The explanations
of the variable names of these data sets are given below:
- mdrd: eGFR measurements
- age.0: baseline age
- fu: follow-up
- salford: base hospital
- male: gender
- smoking: smoking status
- alcohol: alcohol consumption
- diabetes: diabetic conditions
- mcp: co-morbidity
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- stime: survival time
- rrt.event.ind: event indicator variable for RRT
- start: the follow-up time at which the measurements are taken
- stop: the sub-sequent follow-up time of start, but the last value is the survival
time
- rrt.event: time varying event indicator for RRT for each start stop intervals
The models were fitted by using the following script:
##### Separate analyses of longitudinal and survival data
### Longitudinal data analysis
R> install.packages(nlme)
R> library(nlme)
R> lme.fit <- lme(log(mdrd) ~ age.0 + fu + salford + male + smoking +
alcohol + diabetes + mcp,
random = ~ fu | ID, method = "ML",
data = longitudinal.data)
R> summary(lme.fit)
### Survival data analysis
## Cox model with time-varying covariate for RRT
R> install.packages(survival)
R> library(survival)
R> tdep.rrt <- coxph(Surv(start, stop, rrt.event) ~ log(mdrd) + age.0 +
salford + male + smoking + alcohol + diabetes +
mcp, data = longitudinal.data)
R> summary(tdep.rrt)
##### Joint model
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R> install.pacakges(JM)
R> library(JM)
## JointModel function in the JM package fits joint models. It requires
## the fitted objects of separate longitudinal and survival (Cox
## proportional hazards model with baseline covariate) models.
# RRT
R> lme.fit <- lme(log(mdrd) ~ age.0 + fu + salford + male + smoking +
alcohol + diabetes + mcp, random = ~ fu | ID,
method = "ML", data = longitudinal.data)
R> cox.rrt <- coxph(Surv(stime, rrt.event.ind) ~ age.0 + salford +
male + smoking + alcohol + diabetes + mcp,
data = survival.data, x = TRUE)
R> jm.rrt <- jointModel(lme1, cox.rrt, timeVar = "fu",
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Chapter 3
Real-time monitoring of
progression towards renal failure
in primary care patients
This chapter is based on the following paper:
Diggle P. J., Sousa I. and Asar O¨. (2015). Real-time monitoring of progression towards
renal failure in primary care patients. Biostatistics, 16(3): 522–536.
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Abstract
Chronic renal failure is a progressive condition that, typically, is asymptomatic for many
years. Early detection of incipient kidney failure enables ameliorative treatment that
can slow the rate of progression to end-stage renal failure, at which point expensive
and invasive renal replacement therapy (dialysis or transplantation) is required. We use
routinely collected clinical data from a large sample of primary care patients to develop
a system for real-time monitoring of the progression of undiagnosed incipient renal fail-
ure. Progression is characterised as the rate of change in a person’s kidney function
as measured by the estimated glomerular filtration rate (eGFR), an adjusted version of
serum creatinine level in a blood sample. Clinical guidelines in the UK suggest that a
person who is losing kidney function at a relative rate of at least 5% per year should be
referred to specialist secondary care. We model the time-course of a person’s underlying
kidney function through a combination of explanatory variables, a random intercept
and a continuous-time, non-stationary stochastic process. We then use the model to
calculate for each person the predictive probability that they meet the clinical guideline
for referral to secondary care. We suggest that probabilistic predictive inference linked
to clinical criteria can be a useful component of a real-time surveillance system to guide,
but not dictate, clinical decision-making.
Key words: Dynamic modelling; Kidney failure; Longitudinal data analysis; Non-
stationarity; Real-time prediction; Renal medicine; Stochastic processes.
3.1 Introduction
In this paper, we consider the problem of using routinely collected data from a large
sample of people in primary care to monitor the progression of undiagnosed incipient
renal failure. The problem is important because chronic renal failure can be asymp-
tomatic for many years. Early detection followed by initiation of ameliorative treatment
can slow the rate of progression to end-stage renal failure and so postpone the need for
expensive, invasive and often scarce renal replacement therapy (dialysis or transplanta-
tion). Progression towards renal failure is characterised by a sustained fall in a person’s
glomerular filtration rate (GFR). However, direct measurement of GFR is expensive.
For this reason, many specialist renal treatment centres now use as a clinical indicator
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of a person’s renal function an estimated glomerular filtration rate (eGFR). This is cal-
culated from a person’s age, sex, ethnicity and their level of serum creatinine (SCr) as
determined by a blood sample. A widely used formula is the Modification of Diet in






× age−0.203 × 0.742I(female) × 1.21I(black). (3.1)
In common with other published formulae, (3.1) expresses a multiplicative relationship
between eGFR (in ml/min per 1.73m2 of body surface area) and SCr (in µmol/L),
adjusted by age, sex and ethnicity. In our study, information on ethnicity is not available
but the population is mostly Caucasian, and we have ignored the ethnicity component
of (3.1).
The data that we analyse consist of repeated measurements of eGFR taken at irregular,
person-specific follow-up times for 22, 910 primary care patients who have been diagnosed
with pre-disposing conditions for renal failure; these co-morbidities, and other relevant
baseline information, are included in the data as a set of explanatory variables attached
to each person’s record. The data were collected as part of a longitudinal cohort study
run by the Salford Royal Hospital Foundation Trust (SRFT), Greater Manchester, UK.
Our proposed strategy, anticipating to some extent results from the preliminary analysis
of the data as reported in Section 3.5, is to build a dynamic regression model in which
a subject’s rate of change in log-transformed GFR, relative to the expected profile for
all people with the same values of the explanatory variables, is modelled as a stochastic
process B(t), which is realised independently for each person. Using the fitted model,
we then evaluate the predictive distribution of B(t) for each person, conditional on their
data up to and including time t. Under this approach, a person would be flagged as a
candidate for referral to a specialist treatment unit if and when the predictive probability
that their current rate of decrease in GFR exceeds 5% per year is at least pc, where pc
is a threshold value to be specified by the clinician. The choice of pc will determine the
balance between sensitivity and specificity.
The remainder of the paper is organized as follows. In Section 3.2 we give a more de-
tailed description of the SRFT data. Section 3.3 describes our proposed model. Section
3.4 describes associated methods for parameter estimation and for prediction of B(t).
Section 3.5 describes the application to the SRFT data, including model diagnostics
and individual predictions. Section 3.6 presents two simulation studies conducted to
investigate the properties of the estimators of the model parameters and the influence
of distributional and variance structure misspecifications on the predicted probabilities.
Section 3.8 is a concluding discussion.
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Figure 3.1: Log-transformed eGFR measurements against follow-up time (in years).
Data from a representative sample of 6 patients are highlighted as black lines.
3.2 Data
The SRFT data set contains information on 22,910 patients who entered the study
between March 7, 1997 and March 22, 2007 and met the criterion of being at risk for
renal failure. The patients provided a total of 392, 870 values of eGFR. Of the 22,910
patients, 11, 833 (51.65%) were male. Their baseline age ranged between 13.74 and
102.10 years with a median of 67.19 years. The number of eGFR values per patient
ranged between 1 and 305 with a median of 12. Total follow-up time ranged from 0 (i.e.
only one eGFR value) to 10.02 years with median of 4.46 years. Figure 3.1 shows the
complete set of log-transformed eGFR values as a grey scatterplot, with longitudinal
trajectories for a representative sample of 6 patients highlighted as black lines. The
data exhibit substantial variation in eGFR, both between patients and over time within
patients.
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3.3 Model formulation
We consider a general model for the longitudinal eGFR trajectories, of the form
Yij = µi(tij) + Ui +Wi(tij) + Zij . (3.2)
In (3.2), Yij denotes the log-transformed eGFR response for subject i (i = 1, . . . ,M) at
time tij (j = 1, . . . , ni). The function µi(t) is the expected value of the response, which
we represent as a multiple linear regression, hence µi(tij) = Xi(tij)α, where Xi(tij) de-
notes a set of explanatory variables and α denotes the corresponding set of fixed effects
regression parameters to be estimated. The Ui are independent N(0, ω
2) random vari-
ables that represent time-constant differences amongst patients that cannot be explained
by the linear regressions. The Wi(t) are independent copies of a zero-mean, continuous-
time stochastic process representing change in a patient’s GFR over time that cannot
be explained by the linear regressions. We assume that this continuous-time process is
Gaussian, and therefore specified by its covariance function, γ(s, t) = Cov(Wi(s),Wi(t)).
Finally, the Zij are mutually independent N(0, τ
2) random variables representing mea-
surement error in the determination of Yij . Note that the model expresses eGFR as a
noisy version of GFR.
The scalar-valued random effects Ui in (3.2) could be replaced by a second multiple
linear regression, X∗i (tij)U i, where now the U i are mutually independent, multivariate
Normal random variables. The term Wi(tij) in (3.2) might then be omitted. A widely
used example of such specification is the random-intercept-and-slope model in which
Xi(tij) = (1, tij) (Laird and Ware, 1982). However, this is seldom realistic for long
series (Henderson, Diggle and Dobson, 2000). Also, both the clinical context and visual
inspection of longitudinal trajectories for individual patients, typical examples of which
are shown in Figure 3.1, suggest that a random slope is too inflexible. Instead, we model





where Bi(v), the rate of change at time v, is Brownian motion. We set Bi(0) = 0
for every patient i, so that the random effects Ui represent each patient’s deviation
from their expectation at the time of their first eGFR measurement. The conditional
distribution of Bi(t) given Bi(s) for some s < t is Normal, with mean Bi(s) and variance
σ2(t − s). It follows that unconditionally, and using [·] to mean “the distribution of”,
[Bi(t)] = N(0, σ
2t) and Cov(Bi(s), Bi(t)) = σ
2min(s, t). It then follows in turn that
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The process B(t) is Markov, but Wi(t) is not, i.e. in general [Wi(t)|Wi(s),Wi(q)] 6=
[Wi(t)|Wi(s)] for q ≤ s ≤ t. The bivariate process (Bi(s),Wi(t)) is bivariate Gaussian






and is Markov. For details, see Chapter 8 of Ross (1996) and Robinson (2010).
In what follows, we write the model equation (3.2) in the following condensed form,
Y i = Xiα+U i +W i +Zi. (3.5)
Here, Y i = (Yi(ti1), . . . , Yi(tini))
T , Xi = (Xi(ti1)
T , . . . ,Xi(tini)
T )T with Xi(tij) =
(1, Xi1(tij), . . . , Xip(tij)), α = (α0, . . . , αp)
T , U i = UiKi where Ki denotes an ni × 1
matrix of ones, W i = (Wi(ti1), . . . ,Wi(tini))




The distributional properties of U i, Bi, W i and Zi as defined in Section 3.3 induce a
multivariate Normal distribution for Y i,
[Y i] = MVN (Xiα,V i(φ)) ,
where Xi and α are as before. Also,
V i(φ) = ω
2J i + σ
2Ri + τ
2Ii, (3.6)










and Ii is an ni × ni identity matrix.
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We assume that repeated observations belonging to different patients are independent,
i.e. Cov(Y i,Y
′
i) = 0 for i 6= i′. Then, the log-likelihood function can be written as








(Y i −Xiα)T V i(φ)−1 (Y i −Xiα) ,
(3.7)
where θ = (αT ,φT )T and “det” denotes determinant of a square matrix. We obtain the
maximum likelihood estimates (MLE) of the parameters, αˆ and φˆ, by a Fisher-Scoring
algorithm as described in Jennrich and Schluchter (1986). Let φˆ
m
and αˆm denote the






























































, r, s = 1, 2, 3,
(3.10)

























r = 1, 2, 3.
(3.11)










= Ii. In our data analysis and simulations, we assess
convergence by the criterion,
√
(φˆ
m − φˆm+1)T (φˆm − φˆm+1) < 10−10.











and cov(φˆ) = I−1
φˆφˆ
, respectively.
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3.4.2 Prediction
The conditional distributions [Ui|Y i,θ], [Wi(tik)|Y ki ,θ] and, especially, [Bi(tik)|Y ki ,θ],
where Y ki = (Yi1, . . . , Yik)
T , are of scientific interest. The first two are relevant to an
individual’s prognosis, whilst the third is the predictive distribution of the underlying
rate of change, which is the primary target in our application. The explicit forms of these
distributions can be obtained using the properties of multivariate Normal distribution
(Anderson, 1984) as
[Ui|Y i;θ] = N
(
ω2Ki
TV −1i (Y i −Xiα) , ω2
(
1− ω2KTi V −1i Ki
))
, (3.13)




















































where V ki is the variance-covariance matrix of Y
k













and Lki = (t
2
i1, . . . , t
2
ik)
T . Here, we suppress the dependence of
V i on φ. In our application, we substitute the maximum likelihood estimates of θ
into (3.13), (3.14) and (3.15), because estimation errors are negligible compared with
prediction errors. In smaller samples, Bayesian prediction with diffuse priors would
provide a convenient, albeit pragmatic, means of accommodating estimation error.
Similarly, we use properties of the multivariate Normal distribution to obtain the pre-
dictive distributions needed for forecasting Wi and Bi at time tik with lead-time u as





















































where F k,ui =
(
t2i1 (tik + u− ti1/3) , . . . , t2ik (tik + u− tik/3)
)T
. Note that the expec-
tation of [Bi(tik + u)|Y ki ;θ] is the same for all u, but, its variance increases with u.
Whenever a new response Yi,k+1 becomes available, at time tik + u say, we update the
predictions accordingly.
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3.5 Application: SRFT data set
Using log(eGFR) rather than eGFR as our response variable is better-matched to the
clinical criterion for referral to specialist secondary care and improves the empirical fit
of our data to the linear model. On the log-transformed scale eGFR is equivalent to SCr
adjusted for sex and age. Nevertheless, we include sex and age as explanatory variables
because standard formulae such as (3.1) are not optimal for prediction in particular
sub-populations; see, for example, page 606 of Levey and others (2009). It follows that
our predictive inferences are unaffected by whether we use log(eGFR) or log(SCr) as the
response variable. Our main reason for working with eGFR rather than directly with
SCr is that this is more easily interpretable by renal physicians.
We decompose age into age at entry and follow-up time in order to separate cross-
sectional and longitudinal effects of age. This decomposition is strongly supported by a
likelihood ratio criterion: for our final model, the maximised log-likelihood is 312, 251.81
when age at measurement-time is included as a single explanatory variable, 312, 425.83
when the cross-sectional and longitudinal effects of age are separated. Based on our
preliminary analyses we use a piece-wise linear model for the longitudinal age effect
with a change of slope at age 56.5 years. We code sex as 0 for males, 1 for females. The
explicit form of our linear model for a single patient at the jth measurement is therefore
log(eGFR)ij = α0 + α1 Genderi + α2 Baseline agei + α3 tij + α4 max(0, age - 56.5)ij+
Ui +Wi(tij) + Z(tij),
(3.18)
and the corresponding rate of change in kidney function is
α3 + α4I(age > 56.5) +Bi(tij). (3.19)
3.5.1 Estimation
Table 3.1 shows the maximum likelihood estimates and standard errors for the regression
parameters; all are (unequivocally) significantly different from zero. The estimate αˆ0 =
4.6006 establishes the average level of kidney function on entry, whilst αˆ1 = −0.08768
indicates that at study entry, females had 8.4% (= 100∗(exp(−0.0877)−1)) worse kidney
function on average than males. The estimate αˆ2 = −0.0048 indicates that the cross-
sectional effect of age is a loss of kidney function at a rate of approximately 0.5% per
year of age at entry; this is more or less in line with the general population, as would be
expected. The estimate αˆ3 = −0.0232, corresponds to an average loss of kidney function
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Table 3.1: Maximum likelihood estimates of the model parameters and the corre-










at a rate of 2.3% per year until and including age 56.5. This value, together with the
estimate αˆ4 = −0.0075 indicates that the loss of kidney function accelerates to 2.9% after
age 56.5. These estimates of the loss of kidney function reflect the fact that all of the
patients have been diagnosed with pre-disposing conditions for renal failure. Maximum
likelihood estimates of the covariance parameters are ωˆ2 = 0.1111, σˆ2 = 0.0141 and
τˆ2 = 0.0469.
3.5.2 Diagnostics
We apply diagnostic checks on our fitted model, using empirical residuals calculated as
follows. Firstly, for each subject i let ri = Y i −Xiαˆ. Now, denote by Vˆ i the fitted
variance matrix of Y i, obtained by substituting φˆ into (3.6), and write Vˆ i = SiS
T
i ,
where Si is lower triangular. Finally, define the transformed (or standardised) empirical
residual vector for patient i as r∗i = S
−1
i ri.
To check the assumed form of the regression model, we inspect scatterplots of the resid-
uals against the fitted values Yˆij = Xijαˆ, and against the follow-up times, tij . Figure
3.2 shows the two scatterplots with superimposed LOWESS curves (Cleveland, 1979)
obtained using the R function lowess with the default value for the smoothing parame-
ter. There is no discernible systematic pattern in either of the scatterplots and the fitted
smooth curves are close to zero, suggesting a reasonable fit.
To check the assumed form of the covariance structure, we use the variogram of the
empirical residuals (Diggle and others, 2002). The theoretical variogram is the function




ij − r∗ik)2 and uijk = |tij − tik|. The empirical variogram is





all gijk corresponding to each unique value of uijk or, if follow-up times are completely
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Figure 3.2: Left panel: Scatterplot of fitted values versus standardised residuals.
Right panel: Scatterplot of follow-up time (in years) versus standardised residuals.
The dashed line is the zero line, the solid line a LOWESS smooth.
irregular, by averaging all gijk corresponding to values of uijk within a pre-specified set of
intervals. In a well-fitting model, the empirical variogram of the standardised residuals
should fluctuate randomly around 1 when drawn against the lag, u∗ijk = |t∗ij− t∗ik|, where




i ti (Fitzmaurice, Laird and Ware, 2011). Figure 3.3 shows
the empirical variogram for the fitted model. The empirical variogram ordinates show
a decreasing trend from approximately 1.5 to 1 over the range 0 to 2 of differences of
transformed times, and thereafter fluctuate around 1.
We further assess the appropriateness of the assumed variance structure by comparing
the variances of the (unstandardised) empirical residuals rij and the theoretical variance
implied by our model, var(Yij) = ω
2 + σ2t3ij/3 + τ
2, plugging-in the estimates ωˆ2, σˆ2
and τˆ2. The empirical and theoretical variances are drawn in Figure 3.4. The empirical
variances were calculated from binned residuals through time, with bin size of one week,
but with baseline data treated separately, i.e. variances are calculated separately at
baseline and over follow-up measurements between 0+ and 7 days after baseline. The
empirical variance of the baseline residuals is substantially smaller than the variances
of the rest of the residuals, whose variance increases with time but at a substantially
slower rate than the theoretical variance of the fitted model.
We also inspect the distributional assumptions of our model by examining the standard-
ised residuals which are expected to follow standard Normal distribution. Figure 3.5
shows four diagnostic plots. Collectively, these indicate that the residual distribution
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Figure 3.3: The empirical variogram based on the transformed residuals against the
lag based on the transformed time-scale. The variogram ordinates are averaged over


































































































































































































































































































Figure 3.4: The variances of the raw residuals over follow-up time, in years, (dots)
and the theoretical variance function of the fitted model (solid line). Residuals are
binned through time with bin size of one week and bins with less than 30 elements are
omitted. Baseline data are treated separately.
has the expected properties in the main body of the distribution, but heavier tails than
the standard Normal distribution.
Overall, the diagnostic plots show discrepancies between the data and fitted model,
whose influence on predictive performance we investigate in Section 3.6.





























































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Figure 3.5: Diagnostics plots on distributional assumptions based on standardised
residuals. Upper left panel: quantile-quantile plot. Upper right panel: histogram with
Normal density superimposed. Lower left panel: empirical (solid line) and theoreti-
cal (dashed line) cumulative distribution functions. Lower right panel: the difference
between the empirical and theoretical distribution functions.
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3.5.3 Prediction
Figures 3.6 and 3.7 show predictions for four selected patients. Point predictions and pre-
diction intervals for log(eGFR) were calculated from the mean, 2.5% and 97.5% quantiles
of the conditional distribution, [Yij |Xij , αˆ, U˜i, W˜i(tij), τˆ2] = N(Xijαˆ+ U˜i+W˜i(tij), τˆ2),
where U˜i and W˜i(tij) correspond to the mean of [Ui|Y i;θ] and [Wi(tik)|Y ki ;θ], given in
(3.13) and (3.14), respectively. Point and interval predictions for the rate of change were
similarly calculated from the conditional distribution [Bi(tik)|Y ki ;θ] given in (3.15). The
predictive probability, at each follow-up time, for the underlying rate of change being
less than −0.05 was calculated as
p∗i (tik) = P (Bi(tik) < −0.05− αˆ3 − αˆ4I(ageik > 56.5)|Y ki ;θ). (3.20)
The individual predictions for log(eGFR) seem very reasonable. The predicted means
smooth out the erratic fluctuations in measured log(eGFR) and almost all the observed
log(eGFR) measurements are covered by the 95% confidence intervals.
The predictive probability graphs of p∗i (t) as defined by (3.20) are shown in the third
column of Figures 3.6 and 3.7. Our view is that these should guide, rather than deter-
mine, clinical decision-making. From this point of view, the four selected patients show
interestingly different patterns.
1. For patient i = 100, the predictive probability p∗i (t) rises to a value slightly greater
than 0.5 after two years of follow-up, and thereafter fluctuates between about 0.3
and 0.6. The appropriate clinical response would likely depend on factors other
than those that can be encoded in a statistical model, for example the patient’s
general frailty and any co-morbidities.
2. For patient i = 9000, p∗i (t) rises sharply to approximately 0.8 after two years, drops
equally sharply between two and four years, then rises again. This is not atypical
of patients experiencing progression towards renal failure. Indeed, this patient may
well have received treatment within their primary care setting to reverse an acute
loss of kidney function. This pattern is one example of something that the model
cannot be expected to capture, but which does not necessarily negate its value as
a predictive tool.
3. For patient i = 9600, p∗i (t) rises inexorably from 0 to 1 during the first two years
of follow-up. For this patient, referral to secondary care is clearly indicated.
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Table 3.2: Results of the simulation study 1. Columns give the parameter name
(Parameter), the mean (Mean), percentage bias (Bias (%)) and standard deviation
(SD) of the parameter estimates, the mean of the nominal standard errors according
to standard likelihood asymptotic theory (meSE), and the percentage coverage of the
corresponding approximate 95% confidence intervals (CP%).
Parameter Value Mean Bias (%) SD meSE CP(%)
α0 4.6006 4.5874 -0.2869 0.1458 0.1379 94.0
α1 -0.0877 -0.0842 -4.0437 0.0323 0.0323 94.0
α2 -0.0048 -0.0046 -4.5885 0.0029 0.0027 94.0
α3 -0.0232 -0.0227 -1.9979 0.0071 0.0072 95.6
α4 -0.0075 -0.0078 3.3830 0.0041 0.0038 93.4
ω2 0.1111 0.1103 -0.6764 0.0078 0.0079 95.4
σ2 0.0141 0.0141 -0.0806 0.0010 0.0010 94.2
τ2 0.0469 0.0469 -0.0120 0.0008 0.0008 95.8
4. For patient i = 1278800, the progress of p∗i (t) is qualitatively similar to that for
patient i = 113, but on a shorter time-scale and with an unequivocal indication of
referral by 2.5 years.
3.6 Simulations
3.6.1 Simulation study I
We first conducted a simulation study to investigate the properties of the parameter
estimates under the model given by (3.18). For each simulation, the values of the
explanatory variables were those of a random sample of 500 from the 22,910 patients in
the SRFT data. The random effects, Ui, Wi(tij) and Zij were then simulated from their
assumed distributions as described in Section 3.3. The true parameter values for the
simulations were the estimated values from our analysis of the SRFT data, as reported in
Table 3.1. The simulation was replicated 500 times. The mean and standard deviation
of the total number of repeated measurements in the simulated data-sets were 8,599
and 410, the variation being a consequence of the variation in the number of repeated
measurements per patient in the SRFT data. Table 3.2 summarises the results. The
parameter estimates are approximately unbiased. The empirical standard deviations
of the parameter estimates are close to the mean of the nominal asymptotic standard
errors. Coverage is close to the nominal rate of 95%.
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Table 3.3: Results of the simulation study 2. Columns give the mean (Mean) and
standard deviation (SD) of the area under the ROC curve, calculated form 500 replicate
simulations for each cases 1, 2 and 3.
Mean SD
Case 1 0.7574 0.0186
Case 2 (variance structure misspecification) 0.7373 0.0278
Case 3 (heavy-tailed residuals) 0.7558 0.0186
3.6.2 Simulation study II
We conducted a second simulation study to examine the robustness of the predictive
probabilities p∗i (t) to the covariance structure misspecification as depicted in Figures 3.3
and 3.4, and to the heavy-tailed residual distribution as depicted in Figure 3.5.
For each simulation, the values of the explanatory variables were those of a random
sample of 500 from the 22,910 patients in the SRFT data. We considered three data-
generating mechanisms as follows. In the first case, we generated data according to
(3.18) as for simulation study I, again setting the parameter values as the estimates
reported in Table 3.1. In the second case, we added a random effect, U∗i I(t > 0), where
U∗i ∼ N(0, 0.25) and is independent of Ui. The value 0.25 for the variance of U∗i was based
on the empirical variances displayed in Figure 3.4, whilst the assumed independence of
Ui and U
∗
i was based on a preliminary analysis of the SRFT data set using a linear
mixed model with Ui and U
∗
i as the random effects. In the third case, we reverted to
the model given by (3.18), but with the Zij simulated from a t distribution with degrees
of freedom 3, scaled by τ =
√
0.0469. In all three cases, we simulated Bi(tij) together
with Wi(tij) as a bivariate process whose properties are as described in Section 3.3.
Properties of the predictive probabilities, p∗i (t), for the underlying rate of change being
less than −0.05 are summarised by their area under the receiver operating character-
istics (ROC) curve. Area under the ROC curve is calculated as time-invariant, since
the random effects are simulated from their marginal distribution. The simulations are
replicated 500 times for each case. The mean numbers of repeated measurements, over
500 replicate simulations, were 8574, 8533 and 8582 in cases 1, 2 and 3, with standard
deviations 448, 398 and 409, respectively. Table 3.3 shows the mean and standard devi-
ation of the area under the ROC curve in each case. The influence of either covariance
structure misspecification or heavy-tailed residuals is negligible.
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3.7 Computational aspects
All computations were programmed in R and run on a PC with Windows 7 32bit, 4.00
GB RAM and 3.00GHz processor. We have written an R package, lmenssp, available
at http://CRAN.R-project.org/package=lmenssp, that implements parameter estima-
tion and plug-in prediction for a range of non-stationary Gaussian process models. The
supplementary material, available at Biostatistics online includes the SRFT dataset and
gives an exemplary R script for data analysis reported in Section 3.5. The computational
time required for the estimation of the parameters was 60 minutes for the SRFT data
set, 34 seconds for a simulated data set with 500 patients and 8,462 repeated measure-
ments. The predictions require less computational time, since we estimate the model
parameters once and plug-in these estimates into the predictive distributions for each
patient separately. For example, computational times required for predictions were 0.9,
1.0, 2.8 and 8.8 seconds for patients with 10, 100, 203 and 305 observations, respectively.
3.8 Discussion
We have used a large set of longitudinal clinical data to develop a statistical model
for real-time monitoring of progression towards end-stage renal failure. Our specific
objective was to provide predictive probabilities for the event that the underlying rate
of change in a patient’s kidney function is less than −0.05, i.e. a loss of at least 5%
of kidney function per year. The value −0.05 is taken from current UK guidelines for
referral of a primary care patient to specialist secondary care. Our model is a linear
mixed effects model in which between and within patient heterogeneities are captured
by a random intercept and integrated Brownian motion, respectively.
We found discrepancies between the assumed and empirical distribution and variance
structure of the residuals. However, simulations showed that the impact of these discrep-
ancies on the predictive performance of the model is negligible. The finding regarding the
influence of heavy-tailedness is in agreement with the results of Sweeting and Thomp-
son (2012). We considered capturing the behaviour of the empirical variance depicted
in Figure 3.4 by adding a random effect to (3.18) for post-baseline measurements, i.e.
U∗i I(tij > 0) where U
∗ ∼ N(0, ω∗2), but this resulted in a non-identifiable model. We also
considered modelling only post-baseline data, differences from baseline and differences
between successive observations. However, none of these gave any improvement in diag-
nostic performance. Similarly, inclusion of the baseline co-morbidity variables did not
improve the diagnostics. As an alternative to the integrated random walk specification
for the serially correlated random effects, we considered specifying Wi(tij) in (3.18) as
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an integrated Ornstein-Uhlenbeck process (Taylor, Cumberland and Sy, 1994). For this
specification the underlying rate of change follows a stationary Gaussian process with
exponential correlation function. However, the resulting fit suggested that the rate of
change in kidney function behaves as white noise, which is biologically implausible.
The discussion of Figures 3.6 and 3.7 in Section 3.5.3 makes the general point that the
evolution of kidney function in individual patients shows features that are unlikely to
be captured by any statistical model. These features arise for a number of reasons,
including the imperfection of eGFR as a measure of true kidney function (for example,
the underlying serum creatinine assay is affected by changes in muscle mass) and the
transient effects of minor acute illnesses that go unrecorded. For observational time series
of this kind, fit to the data is less important than the ability to address the primary
research question which is the probability that a patient is losing kidney function at a
rate of 5% or more per year.
Our current algorithm for prediction requires inversion of matrices of dimension ni by
ni, where ni is the current number of eGFR measurements available for the ith patient.
In principle, it would be computationally more efficient to use a Kalman filter algorithm
(Kalman, 1960) to update predictive probabilities based on the most recent results,
rather than re-calculating from scratch whenever new eGFR measurements are added
to the data. By exploiting the result that the bivariate process (Bi(t),Wi(t)) is Markov,
we can represent our model as a local linear trend model (Robinson, 2010; Durbin and
Koopman, 2012). However, this formulation assumes that the rate of change is constant
between successive measurements, which introduces an element of approximation. In
our data, the maximum value of ni is 305, most are much smaller and the associated
exact computations are not burdensome. Similarly, in principle we might want to allow
for parameter uncertainty when calculating the predictive probabilities, for example
by assigning Bayesian priors to the model parameters, θ say, and replacing the plug-
in predictive distribution, [Bi(tik)|Y i; θˆ], by
∫
[Bi(tik)|Y i;θ][θ|Y i]dθ. However, in our
application the difference between the two is negligible as the prediction error in Bi(t)
dominates the estimation error in θ.
3.9 Online supplementary material: R codes
## R script to apply to SRFT data set the methodology used in the paper
# loading the package
R> library(lmenssp)
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# reading the data set into R
R> srft.data <- read.csv("srft.data.csv", header = T)
# obtaining the parameter estimates
R> fit.ibm <- lmenssp(log(egfr) ~ sex + bage + fu + pwl,
+ data = srft.data, id = srft.data$id,
+ process = "ibm", timeVar = srft.data$fu,
+ tol = 1e-10, maxiter = 100, silent = FALSE)
R> fit.ibm
# obtaining the predictive distributions of [U_i|Y_i],
# [W_i(t_{ik})|Y_i^k] and [B_i(t_{ik})|Y_i^k]
# for patients with IDs = 100, 9000, 9600 and 1278800, respectively
R> subj.id <- c(100, 9000, 9600, 1278800)[1]
R> filter <- filtered(log(egfr) ~ sex + bage + fu + pwl,
+ data = srft.data, id = srft.data$id,
+ process = "ibm", timeVar = srft.data$fu,
+ estimate = fit.ibm$estimate[, 1],
+ subj.id = subj.id)
R> filter
# drawing Figures 3.6 & 3.7
R> Xi <- as.matrix(cbind(1, srft.data[srft.data$id == subj.id,
+ c("sex", "bage", "fu", "pwl")]))
R> Yi <- log(as.matrix(srft.data[srft.data$id == subj.id, c("egfr")]))
R> timei <- srft.data[srft.data$id == subj.id, "fu"]
R> pwli <- srft.data[srft.data$id == subj.id, "pwl"]
R> fitted.mean <- Xi %*% fit.ibm$estimate[1 : 5, 1, drop = F] +
+ matrix(rep(filter$u[1, "mean"], nrow(Xi))) +
+ matrix(filter$w[, "mean"])
R> fitted.var <- fit.ibm$estimate[8, 1]
R> threshold <- -0.05 - fit.ibm$estimate[4, 1] -
+ fit.ibm$estimate[5, 1] * as.numeric(I(pwli > 0))
R> par(mfrow = c(1, 3))
R> pllim <- fitted.mean - 1.96 * sqrt(fitted.var)
R> pulim <- fitted.mean + 1.96 * sqrt(fitted.var)
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R> plot(timei, Yi, type="p", ylab="log(eGFR)",
+ xlab = "Follow-up time (in years)",
+ ylim = c(min(min(Yi), min(pllim)) - 0.01,
+ max(max(Yi), max(pulim)) + 0.01),
+ pch = 19, col = "black")
R> points(timei, fitted.mean, col = "black", type = "l")
R> points(timei, pllim, col = "black", type = "l", lty = 2)
R> points(timei, pulim, col = "black", type = "l", lty = 2)
R> plot(timei, filter$b[, "mean"], ylab = expression(tilde(B)),
+ xlab = "Follow-up time (in years)",
+ ylim = c(min(qnorm(0.025, mean = filter$b[, "mean"],
+ sd = sqrt(filter$b[, "variance"]),
+ lower.tail = TRUE)) - 0.1,
+ max(qnorm(0.975, mean = filter$b[, "mean"],
+ sd = sqrt(filter$b[, "variance"]),
+ lower.tail = TRUE)) + 0.1),
+ type = "l")
R> points(timei, qnorm(0.025, mean = filter$b[, "mean"],
+ sd = sqrt(filter$b[, "variance"]),
+ lower.tail = TRUE),
+ type = "l", lty = 2, col = "black")
R> points(timei, qnorm(0.975, mean = filter$b[, "mean"],
+ sd = sqrt(filter$b[, "variance"]),
+ lower.tail = TRUE),
+ type = "l", lty = 2, col = "black")
R> plot(timei, pnorm(threshold, mean = filter$b[, "mean"],
+ sd = sqrt(filter$b[, "variance"])), ylim=c(0,1),
+ ylab = "Probability", xlab = "Follow-up time (in years)",
+ pch = 20, type = "l")
# calculating the probabilities of meeting the clinical guideline
# of losing renal function
# at a rate of at least 5% per year
R> pnorm((threshold), filter$b[, "mean"], sqrt(filter$b[, "variance"]))
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Chapter 4
Acute kidney injury amongst
chronic kidney disease patients: a
case-study in statistical modelling
This chapter is based on the following paper:
Asar O¨., Ritchie J., Kalra P. A. and Diggle P. J. (2015). Acute kidney injury amongst
chronic kidney disease patients: a case-study in statistical modelling. Submitted to
Statistics in Medicine.
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Abstract
Chronic kidney disease (CKD) and acute kidney injury (AKI) are two important kidney
related health problems. The former is defined as enduring kidney damage or decreased
kidney function, the latter as a sudden fall in the kidneys’ excretion function. These two
conditions are now recognised to be strongly associated. In this study, we investigate the
influence of AKI on long-term kidney function amongst patients already diagnosed with
CKD. We develop a longitudinal statistical model with Mate´rn correlation structure and
multivariate t-distributed stochastic components. We also specify three change-points
that describe the typical trajectory of an AKI event. We use maximum likelihood
estimation implemented with an expectation-maximisation algorithm to estimate the
model parameters, and best linear unbiased prediction to predict the random effects.
Our case-study uses data from an on-going cohort study of chronic kidney patients at
Salford Royal NHS Foundation Trust, Manchester, UK. A simulation study is conducted
to investigate the properties of the estimators.
Key words: Dynamic modelling, longitudinal data analysis, mixed-effects models, re-
nal medicine, robust distributions, stochastic modelling.
4.1 Introduction
Chronic kidney disease (CKD) covers a wide range of disorders that affect the function
and structure of the kidneys (El Nahas and Levin, 2009; Levey and Coresh, 2012). It is
defined as kidney damage and/or decreased kidney function that continues for at least
three months. CKD can be asymptomatic for many years and is usually detected during
the assessment of co-morbid conditions. Most cases are characterised by a gradual
decline in kidney function, which might take decades or a small minority of patients
might not progress at all, whilst aggressive cases can lead to kidney failure within months.
Common causes of CKD are cardiovascular disease and diabetes mellitus. It has now
been recognised as an important public health problem, with a worldwide prevalence of
8-10%, whilst prevalence in high-risk sub-populations can exceed 50% (Jha et al., 2013;
Eckardt et al., 2013).
Acute kidney injury (AKI) is defined as a sudden fall in kidneys’ excretion function,
over a period of hours or, at most, a few days. It represents an acute response to any of
a number of disorders that affect the kidneys (Bellomo, Kellum and Ronco, 2012). AKI
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is common, and potentially catastrophic, in hospitalised and critically-ill patients. For
example, Finlay et al. (2013) reports that the prevalence of AKI amongst patients who
were admitted to acute medical units was 18%. Its severity ranges from mild renal im-
pairment to complete renal failure and death. Even early-stage and short-term episodes
of AKI need to be treated carefully to minimise the risk of severe complications (Chawla
et al., 2014). AKI is associated with high mortality and long-term complications (Kerr
et al., 2014). For example, Bellomo, Kellum and Ronco (2012) reports that mortality
rates due to AKI amongst criticaly-ill patients were 53% and 44.7% in two different
clinical trials. Although selected cases of AKI, e.g. vasculitis, have specific therapeutic
treatment options, in most cases intervention is limited to identification and treatment
of the underlying cause.
CKD and AKI are highly associated syndromes: an AKI episode can lead to the onset
of CKD or worsen the severity of existing CKD (Chawla and Kimmel, 2012; Eckardt
et al., 2013; Lameire et al., 2013; Chawla et al., 2014). Conversely, CKD confers an
approximately ten-fold increase in the risk for AKI (Chawla et al., 2014). Nevertheless,
the full implications of AKI for long-term kidney function remain an open research area
(Lameire et al., 2013; Chawla et al., 2014).
In this study, we investigate the influence of AKI on the long-term evolution of kidney
function amongst CKD patients. Our data are taken from the Chronic Renal Insuffi-
ciency Standards Implementation Study (CRISIS; Eddington et al., 2010; Hoefield et
al., 2010). AKI events are declared retrospectively by inspection of repeated serum
creatinine (SCr) measurements, according to the guidelines given by the Kidney Dis-
ease: Improving Global Outcomes (KDIGO) Acute Kidney Injury Work Group guideline
(KDIGO, 2012). We develop a clinically-informed, formal description of an AKI episode
that includes three change-points in the longitudinal evolution of a patient’s kidney
function. A gap of greater than three days between blood tests is used to define a new
AKI episode.
We develop a linear mixed effects model for a patient’s repeated measurements that
combines fixed effects, a random intercept, a stationary stochastic process with Mate´rn
covariance structure (Mate´rn, 1960) and mutually independent random measurement
error. Diggle (1988) proposed a model of this kind under Gaussian distributional as-
sumptions and powered correlation family. We extend this by allowing stochastic compo-
nents of the model to follow a multivariate t distribution, because diagnostic tests of the
Gaussian model gave clear evidence of long-tailed behaviour in the CRISIS data set, and
Mate´rn correlation family is wider than the powered correlation family. We estimate
model parameters by maximum likelihood (ML), using an expectation-maximisation
(EM) algorithm (Dempster, Laird and Rubin, 1977) that exploits the normal-gamma
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hierarchical representation of the t distribution. We use exploratory methods to identify
change-points in the longitudinal profile during an AKI episode. All computations are
carried out in R (R Development Core Team, 2014) by exploiting the lmenssp package
(Asar and Diggle, 2014).
The paper is organised as follows. In Section 4.2, we give details of the data set, the
clinical definition of an AKI episode and our algorithm for identifying each AKI episode
within the CRISIS data set. In Section 4.3, we describe the formulation of our statisti-
cal model and the associated inferential methods. In Section 4.4, we present the results
from our analysis of the CRISIS data set, and Section 4.5 provides diagnostic results.
We conduct a simulation study in Section 4.6 and close the paper with a concluding
discussion. Whilst R scripts are provided in Section 4.8, a sensitivity analysis on cen-
soring longitudinal trajectories of the patients with no AKI events can be found in the
appendix.
4.2 Data, definition of AKI and the change-points
4.2.1 CRISIS cohort
Our data are obtained from the Chronic Renal Insufficiency Standards Implementation
Study (CRISIS) run by the Salford Royal NHS Foundation Trust (SRFT). CRISIS is an
on-going observational study of all-cause CKD. In the UK, renal services are based on a
hub and spoke system with a single main centre supporting care at many smaller local
trusts. For patients in the CRISIS study the main centre is SRFT, with six district gen-
eral hospitals. Measurement of a patient’s renal function uses the four-variable MDRD






× age−0.203 × 0.742I(female) × 1.21I(black), (4.1)
where eGFR denotes estimated glomerular filtration rate (in mL/min 1.73m2 of body
surface area) and SCr serum creatinine (in µmol/L), except that the ethnicity factor in
(4.1) is ignored, since most of the patients in the CRISIS data set were Caucasian.
The data set covers 2,289 patients who entered the study between 15/11/2000 and
28/02/2013. The patients provided a total of 48,382 repeated measurements of eGFR,
in 5,480 (11.3%) of which the patients were hospitalised. Amongst the 2,289 patients,
1,415 (61.8%) were male, 2,202 (96.2%) were Caucasian, 682 (29.8 %) had SRFT as their
base hospital, 1,540 (67.3%) were current- or ex-smokers, 1,097 (47.9%) were alcohol-
consumers, 723 (31.6%) had been diagnosed with diabetes mellitus and 455 (19.9%) had
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Figure 4.1: Log-transformed eGFR measurements against follow-up time (in years)
in background as grey scatter-plot. Data from a representative sample of 8 patients are
highlighted as black lines.
a history of coronary artery disease, defined as previous myocardial infarction and/or
coronary re-vascularisation procedure. Baseline age ranged between 20 and 94.3 (me-
dian=66.8). The number of repeated measurements per patient ranged between 1 and
280 (median=13). Total follow-up time ranged between 0 (i.e. only one measurement)
and 10.9 years (median=2.6).
The log-transformed eGFR measurements are displayed in Figure 4.1 as a gray scatter-
plot, with longitudinal trajectories for a representative sample of 8 patients highlighted
as black lines. These data suggest considerable heterogeneity between patients, in respect
of both their level of kidney health on entering the study and the pattern of longitudinal
evolution in their kidney function. Individual longitudinal trajectories of eGFR typically
show non-linear features, some at least of which are associated with AKI episodes.
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Table 4.1: AKI stages based on the KDIGO AKI guideline. RC denotes relative
change in SCr, calculated as (SCrt − SCrs)/(SCrs), where s and t are two time points
and s < t.
Stage Criterion
1 0.5 ≤ RC < 1 or
increase of 26.5 µmol/L or greater
2 1 ≤ RC < 2
3 2 ≤ RC or
increase to or greater than 353.6 µmol/L or
initiation of RRT
4.2.2 Clinical definiton of AKI
AKI events are decided based on inspecting repeated SCr measurements retrospectively,
according to the KDIGO AKI guideline (KDIGO, 2012, pg. 8), presented in Table
4.1. In-patient episodes are considered to be the main periods where AKI might have
occurred. This is inspected by comparing the following SCr measurement combinations:
• most recent out-patient measurement and first in-patient measurement,
• first in-patient measurement and other in-patient measurements, and
• successive in-patient measurements.
Out-patient AKI episodes are defined as in Table 4.1 where measurements are separated
by less than two days. Where successive out-patient measurements are performed within
two to seven days of each other, AKI episodes are defined only by relative change in
serum creatinine. Multiple AKI events occurring within three days are considered as
belonging to a single AKI episode with the most severe grade.
The distribution of the number of AKI events per patients for the CRISIS data set are
displayed in Table 4.2. For example, 1,576 (68.9%) patients did not experience any AKI
events, 408 (17.8%) experienced only one AKI event (any stage), 126 (5.5%) experienced
two AKI events (any stage), and so on. In total, 713 (31.1%) patients experienced at
least one AKI event. These patients had total amount of 1,863 AKI events, where 1,198
(64.3%) of the events were stage 1, 37 (2.0%) stage 2 and 628 (33.7%) stage 3. Whilst
the patients who did not have any AKI had total amount of 21,176 (43.6%) repeated
measurements, the ones who had AKI had 27,401 (56.4%) repeated measurements.
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Table 4.2: AKI distribution of the CRISIS data set.
AKI events Patients AKI events Patients
0 1,576 (68.9%) 5 24 (1.0%)
1 408 (17.8%) 6 15 (0.7%)
2 126 (5.5%) 7 11 (0.5%)
3 59 (2.6%) ≥ 8 43 (1.8%)
4 27 (1.2%)
4.2.3 Data
In this study, we specifically consider the influence of the first AKI events on kidney
function and censor the longitudinal trajectories at the second AKI. In total, 8,514
repeated measurements on 305 patients (number of patients who had more than one
AKI event) are discarded because of this censoring. Data falling into the first AKI
episodes are also omitted as they are abrupt observations and the interest is in comparing
trajectories for pre- and post-AKI periods. 1,234 repeated measurements on 713 patients
(number of patients who had at least one AKI event) are discarded, because they fall
into the first AKI episode.
Amongst the first AKI events, 379 (53.2%) are stage 1, 5 (0.7%) stage 2 and 329 (46.1%)
stage 3. As the number of stage 2 AKI is low, we proceed by combining stage 2 and 3
into a single stage. The patients with stage 1 AKI had total number of 11,153 repeated
measurements, of which 6,954 (62.4%) belong to post-AKI period, 4,199 (37.6%) belong
to pre-AKI period. The patients with stage 2 or 3 AKI had total number of 6,500
repeated measurements, of which 5,425 (83.5%) belong to pre-AKI period, 1,075 (16.5%)
belong to post-AKI period.
Eight patients’ data are displayed in Figures 4.2 and 4.3. Solid dots denote log-transformed
eGFR measurements. Amongst these patients, whilst the ones with ID = 474 and 1220
did not experience any AKI, the ones with ID = 26 and 46 experienced stage 1 AKI, at
years 1.74 and 1.73, respectively, the ones ID = 430 and 875 experienced stage 2 AKI,
at years 1.86 and 1.75, respectively, and the ones with ID = 1 and 187 experienced stage
3 AKI, at years 8.03 and 4.15, respectively. Time at AKI are indicated on the x− axis.
4.2.4 Change-points
We assume that there are three change-points in the longitudinal trajectories of the
patients who experienced AKI. Amongst these, second change-points are placed at the
follow-up times at which AKI events occur, ci. These change-points are patient-specific



















































lll l l l ll
l ll l lll l l




































































































































































































































































































































































































































































































































































































































































































































































































































































































































Acute kidney injury amongst chronic kidney disease patients 77
and known. On the other hand, the first change-points are assumed to be at a time
somewhere before AKI events occur. These change-points correspond to accelerations
in the loss of kidney functions that precede occurrence of AKI events. The rationale for
them are in line with the statement of Bellomo, Kellum and Ronco (2012) for replacing
the term “acute renal failure” by “acute kidney injury”:
“... to emphasise that a continuum of kidney injury exists that begins long before suffi-
cient loss of excretory kidney function...”
The first change-points are assumed to be different in terms of experiencing stage 1 and
stage 2 or 3 AKI, but are assumed to be common for the patients within these groups. In
other words, whilst ci−a1 is the first change-point for the patients who experienced stage
1 AKI, ci−a2 is the first change-point for the patients who experienced stage 2 or 3 AKI.
The values of a1 and a2 are unknown and to be decided by the following exploratory
methods. Data are aligned at the AKI occurrences and LOWESS curves (Cleveland,
1979) with different smoothing parameters are drawn. Also, profile likelihood based on
linear model with independent errors is considered. The third change-points, on the
other hand, are assumed to occur after AKI events. These change-points correspond to
the end of recovery in kidney function, which the patients are assumed to have after
an AKI event. Here, these change-points are based on the experiences of the physicians
who run the CRISIS cohort. Similar to the first change-points, the third change-points
are assumed to be different for stage 1 and stage 2 or 3 AKI experience, but are assumed
to be same for the patients within these groups. We denote these change-points with
ci+b1 and ci+b2 for the stage 1 and stage 2 or 3 AKI groups, respectively. b1 and b2 are
also assumed to be unknown and to be decided by the exploratory methods discussed
above.
We call the change-point before AKI occurrence as “acceleration point”, and the one after
AKI occurrence as “end-of-recovery point”. We then label four periods based on these
change-points as, pre-acceleration: from study entry to acceleration point, acceleration:
from acceleration point to AKI occurrence, recovery: from AKI occurrence to end-of-
recovery point, post-recovery: after end-of-recovery point.
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4.3 Model
4.3.1 Formulation
We consider a class of linear mixed effects models for repeated blood samples data. The
general form of the model is
Y i = Xiα+U i +W i +Zi. (4.2)
Here, Y i = (Yi1, . . . , Yini)
T denotes log-transformed eGFR measurements for subject
i (i = 1, . . . ,m) at time points ti = {ti1, . . . , tini}. Xi = (Xi1, . . . , Xini)T with Xi. =
(1, Xi11, . . . , Xip1)
T are explanatory variables that might include time-independent and/or
time-dependent variables, and α = (α0, . . . , αp)
T are the corresponding fixed effects pa-
rameters to be estimated. U i = (Ui, . . . , Ui)
T (with ni identical elements) are patient-
specific random intercepts that account for the between-patient heterogeneity in kidney
function at study entry. W i = (Wi(ti1), . . . ,Wi(tini))
T are subject-and-time-specific
random-effects that account for serial correlation arising from the repeated measure-
ments belonging to the same patients. Finally, Zi = (Zi1, . . . , Zini)
T are mutually
independent random measurement error.
The conditional distributions ofU i,W i andZi given γi, an unobserved random variable,
and the marginal distribution of γi are specified as
























[γi] = Gamma (ν/2, ν/2) , (4.6)
where [·] denotes the “distribution of”, J i is an ni × ni matrix of 1s, Ri is an ni × ni
matrix, details of which to be discussed below, Ii is the ni × ni identity matrix, and
ν/2, is the shape and rate parameter of the gamma distribution, with ν > 0. The
specifications in (4.3)-(4.6) equivalently imply that
[U i] = MV t
(
0, ω2J i, ν
)
, (4.7)










Here, U i, W i and Zi are uncorrelated, but not independent, when ν <∞.
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κ−1 exp(−x)dx is the gamma function, Kκ is a modified Bessel
function with order κ, φ > 0 is a scale parameter, κ > 0 is a shape parameter
which controls the smoothness of the process, W (·). Mate´rn correlation family indi-
cates stationarity for W (·), covers different degrees of smoothness depending on the
value of κ and indicates that W (·) is ceiling(κ) − 1 times mean-square differentiable.
Special cases include, amongst others, exponential correlation function when κ = 0.5
as {Ri}r,s = exp(−|tir − tis|/φ) and Gaussian correlation function when κ → ∞ as
{Ri}r,s → exp(−|tir − tis|2/φ). These cases correspond to mean-square continuous but
non-differentiable and infinitely mean-square differentiable processes, respectively. Dig-
gle and Ribeiro (2007) discusses that κ is poorly estimated as φ and κ are not orthogonal,
and proposes to set κ to some specific values covering a range of smoothness. In this
study, we follow their suggestion and fix κ at, e.g. 0.5, 1.5, 2,∞. These values respec-
tively correspond to mean-square continuous but non-differentiable, once-differentiable,
twice-differentiable and, infinitely mean-square differentiable processes. Explicit calcu-
lations for Mate´rn correlation family are not available, but approximate calculations can
be obtained, e.g. as implemented in the matern function of the R package geoR (Diggle
and Ribeiro, 2007).
The distributional properties of Ui, Wi, Zi and γi induce Y i to have the following
conditional and marginal distributions,







[Y i] = MV t (Xiα,V i, ν) , (4.12)
where V i = ω
2J i + σ
2Ri + τ
2Ii. Here, the variance-covariance matrix of Y i is
ν
ν−2V i,
for ν > 2. When ν > 1, Xiα is the mean of the multivariate t distribution, hence
the interpretations of the estimates of α are same as with the normal model, i.e. the
interpretations are for average changes in the response variable. As ν →∞, [Y i] distr.−−−→
MVN (Xiα,V i). In other words, when ν →∞, γi → 1, the model (4.2) approximates
to the multivariate normal model. For further details of the multivariate t distribution,
see Kotz and Nadarajah (2004). Multivariate slash or multivariate contaminated normal
distributions can also be obtained by specifying the distribution of γi other than gamma,
in (4.3)-(4.6), e.g. see (Rosa, Padovani and Gianola, 2003).
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4.3.2 Inference
We estimate the model parameters, θ = {α, ω2, σ2, φ, τ2, ν}, by ML estimation with an
E-M algorithm, following Liu and Rubin (1995) and Pinheiro, Liu and Wu (2001). θ
does not include κ, since we set it to known values. Data belonging to different patients
are assumed to be independent. We specifically consider that the random-effects are
integrated out and the complete data for patient i consist of Y i and γi, where whilst
Y i are observed, γi is unobserved and treated as missing data. Then, the complete data
likelihood for subject i is
[Y i, γi] = [Y i|γi][γi], (4.13)
where [Y i|γi] and [γi] are given as in (4.11) and (4.6), respectively. The E-M algorithm
then includes the following steps:
E-step: Given θˆ, calculate γˆi = E(γi|Y i) based on









where δi = (Y i −Xiα)TV −1i (Y i −Xiα).
M-step 1: Given γˆi, maximise the expected-log-likelihood, given Y i, based on
[Y i|γi] with respect to θ−ν .






















log(ν)− ν + ni
2
log (ν + δi)
}
.
Parameter estimates in M-step 1 can be obtained by using available software for multi-
variate normal mixed models with Mate´rn correlation family, since when γi is known, the
multivariate t model in (4.2) reduces to Y ∗i = X
∗
iα+U i+W i+Zi, where Y
∗
i = Y i
√
γˆi
and X∗i = Xi
√
γˆi, and [U i], [W i] and [Zi] are all multivariate normal. We use the
R package lmenssp for this purpose. On the other hand, R function optimize is used
for M-step 2. In M-step 2, νˆ might also be obtained by maximising the expected-log-
likelihood, given Y i, based on [γi], but the resulting procedure involves a term that is
not available in a closed-form and this might result the algorithm to be extremely slow
(Liu and Rubin, 1995; Pinheiro, Liu and Wu, 2001). The main advantage of exploiting
(4.12) in M-step 2 is that it is free of γi.
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At convergence, large-sample variance-covariance matrix of αˆ, using expected Fisher












at θˆ−α. On the other hand, variance-covariance matrix of θ−α are calculated as the
inverse of the negative Hessian matrix, which is approximated numerically by the central-
difference method.
The model in (4.2) can be equivalently written as, Y i = Xiα+DiBi+Zi, where Di =
(1Ti , Ii) with 1i is vector of 1s of length ni, and Ii as before andBi = (Ui,Wi1, . . . ,Wini)
T .
The conditional distribution, [Bi|Y i, γi], can then be obtained by using multivariate
normal theory (Anderson, 1984), as [Y i,Bi|γi] is multivariate normal,










J i −DTi V −1i Diψi
))
, (4.16)
where ψi/γi is the variance-covariance matrix of [Bi|γi], V i and J i are as before. We
plug-in in (4.16) θˆ−ν , and γˆi. We opt to proceed by replacing γˆi to calculate [Bi|Y i, γi],
since explicit forms of conditional distributions based on multivariate t distribution is
not available (Arellano-Valle and Bolfarine, 1995).
4.4 Results
We analyse the data for all the patients, i.e. the ones without any AKI events and the
ones with AKI events as presented in Section 4.2.3, by using the model given in Equation
4.2. There are a total of 38,829 repeated measurements belonging to 2,289 patients. The
main explanatory variables used in the analysis are listed in Table 4.3. Piecewise linear
terms in the slopes based on the change-points are considered as additional explanatory
variables.
We build mixed models with varying shape parameter for the Mate´rn correlation fam-
ily, κ = 0.5, 1.5, 2.5,∞, whilst keeping the covariate sets same. Respective maximised
log-likelihood values are 14,534.43, 13,343.70, 13,046.89, and 12,635.39. Therefore, we
proceed with the results of the model with κ = 0.5. The change-points are identified as
a1 = 0.3 years (≈ 110 days), b1 = 0.1 (≈ 37) a2 = 0.4 (≈ 146), and b2 = 0.15 (≈ 55).
The ML estimates for both the multivariate t and normal models are displayed in Table
4.4. Multivariate t distribution assumption clearly provides a better fit for the CRISIS
data set compared to the multivariate normal distribution assumption, as indicated by
the maximised log-likelihoods, 14,534.43 vs. 8,892.63.
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4.4.1 Population-averaged results
The parameter estimate αˆ0 = 3.5674 denotes average kidney function level (in log-
scale) at study entry. αˆ1 = −0.0366 denotes mean loss of kidney function per year at
a rate of approximately 3.6% (= (exp(−0.0366) − 1) ∗ 100) for patients who did not
have any AKI. At the same time, it corresponds to the slope of the pre-acceleration
period for the patients who experienced stage 1 and stage 2 or 3 AKI, and we call αˆ1
as αˆpre−acc−1 and αˆpre−acc−2 for these group of patients, respectively. αˆ2, αˆ3 and αˆ4
denote the changes in the slope at 0.3 years prior to stage 1 AKI occurrence, at stage 1
AKI occurrence and 0.1 years after stage 1 AKI occurrence, respectively. Together with
αˆpre−acc−1, they collectively establish the slopes for the acceleration period, αˆacc−1 =
−0.4436 (SE = 0.0249), for the recovery period, αˆrec−1 = 0.2653 (SE = 0.0684),
and for the post-recovery period, αˆpost−rec−1 = −0.0942 (SE = 0.0110). Similarly,
αˆ5, αˆ6 and αˆ7 denote the changes in slope at 0.4 years prior to stage 2 or 3 AKI
occurrence, at stage 2 or 3 AKI occurrence and 0.15 years after stage 2 or 3 AKI
occurrence, respectively. Together with αˆpre−rec−2, they collectively establish the slopes
for the acceleration period, αˆacc−2 = −0.7630 (SE = 0.0239), for the recovery period,
αˆrec−2 = 0.5591 (SE = 0.1010), and for the post-recovery period, αˆpost−rec−2 = −0.0830
(SE = 0.0262). These parameter estimates are depicted in Figure 4.4, for example, for
a (hypothetical) female patient with baseline age of 67 years, whose base hospital was
not SRFT, was not smoking, was not consuming alcohol, did not have diabetes mellitus
and co-morbidity history at study entry and was followed for 2 years. In addition to
the results of the multivariate t distribution (in black), the results of the multivariate
Normal distribution (in grey) as presented in Figure 4.4.
Key findings regarding the influences of AKI occurrences on kidney function are sum-
marised below:
• The rate of kidney function loss significantly accelerates at 0.3 years prior to stage
1 AKI occurrence; p-value is <0.0001 for H0 : αpre−acc−1 = αacc−1. Whilst the
rate of kidney function loss was 3.6% in the pre-acceleration period, it became
35.8% in the acceleration period.
• The rate of kidney function loss significantly accelerates at 0.4 years prior to stage
2 or 3 AKI occurrence; p-value is <0.0001 for H0 : αpre−acc−2 = αacc−2. Whilst
the rate of kidney function loss was 3.6% in the pre-acceleration period, it became
53.4% in the acceleration period.
• After experiencing stage 1 AKI, patients significantly recovered their kidney func-
tion until 0.1 years after AKI occurrence with a rate of 30.4%; p-value is <0.0001
for H0 : αrec−1 = 0.


















Figure 4.4: Average kidney function evolution for a hypothetical patient. Results
based on multivariate t model are in black, results based on multivariate Normal model
are in grey. Straight lines denote mean profiles for no AKI occurrence; dashed lines
denote mean profiles for stage 1 AKI occurrence; dashed lines with dots denote mean
profiles for stage 2 or 3 AKI occurrence. Solid dots denote change-points for stage 1
AKI, solid squares denote change-points for stage 2 or 3. Follow-up time 1 is the time
at AKI occurrence for both stage 1 and stage 2 or 3 AKI.
• After experiencing stage 2 or 3 AKI, patients significantly recovered their kidney
function until 0.15 years after AKI occurrence with a rate of 74.9%; p-value is
<0.0001 for H0 : αrec−1 = 0.
• The slope of the post-recovery period for stage 1 AKI is negative, αpost−rec−1 =
−0.0942, and significantly different form 0; p-value is<0.0001 forH0 : αpost−rec−1 =
0. Its magnitude is significantly larger than the magnitude of the slope of the pre-
acceleration period, αˆpre−acc−1 = −0.0366; p-value = 0.0001 for H0 : αpre−acc−1 =
αpost−rec−1. The rate of kidney function loss become 9.0%, whilst it was 3.6% at
the pre-acceleration period.
• The slope for the post-recovery period for stage 2 or 3 is negative, αˆpost−rec−2 =
−0.0830, and significantly different form 0; p-value is 0.0015 for H0 : αpost−rec−2 =
0. However, its magnitude is not significantly larger than the magnitude of the
slope of the pre-acceleration period, αˆpre−acc−2 = −0.0366; p-value = 0.0769 for
H0 : αpre−acc−2 = αpost−rec−2.
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Here, the decision of failing to reject the hypothesis, H0 : αpre−acc−2 = αpost−rec−2, is
surprising, because there is not enough evidence to say that the slopes at post-recovery
periods for the patients with stage 1 AKI and stage 2 or 3 AKI are different; p-value
for H0 : αpost−rec−1 = αpost−rec−2 is 0.6929. This might be explained by the number
of observations falling into the post-recovery periods. There are 617 observations in
this period for patients with stage 2 or 3 AKI. On the other hand, there are 4,199
observations in this period for patients who had stage 1 AKI. The influence of the number
of observations might also be seen in the width of the confidence intervals: whilst the
estimate (95% confidence interval) for αpre−acc−1−αpost−rec−1 is 0.0576 (0.0356, 0.0797),
it is 0.0464 (-0.0050, 0.0978) for αpre−acc−2 − αpost−rec−2. Based on these, testing the
following hypothesis might be more suitable to test the influence of AKI on kidney
function, H0 : α1 = (αpost−rec−1 +αpost−rec−2)/2. Whilst the related p-value is found to
be 0.0003, the estimate (95% confidence interval) of α1− (αpost−rec−1 +αpost−rec−2)/2 is
0.0520 (0.0239, 0.0802). Based on these results, we can say that the influence of AKI on
kidney function is significant, and the collective loss of kidney function after recovery is
8.5%, whilst it was 3.6% in the pre-acceleration period.
A one year increase in the baseline age was associated with an average loss of kidney
function at an approximate rate of 0.4%. Patients whose base hospital was SRFT
were found to have approximately 20.6% better kidney function compared to the ones
whose base hospital was not SRFT. Males had 4.9% better kidney health compared to
females at study entry. Alcohol consumers were associated with 5.5% better kidney
function at study entry compared to the patients who were abstainers. This is indeed
an unexpected result, yet might be considered natural as regression equations do not
generally imply causation. Another explanation for this might be that the patients
with worse kidney health might be abstinent from alcohol. On the other hand, some
previous works also discuss better kidney function amongst alcohol consumers, e.g. see
Kim, Kim and Song (2014). Patients with diabetes mellitus had 11.0% worse kidney
health compared to the patients without diabetes mellitus. No significant relationships
were found between kidney function and smoking or co-morbidity; respective p-values
are 0.4592 and 0.8214. ML estimates of the covariance parameters were found to be
ωˆ2 = 0.1275, σˆ2 = 0.1327, φˆ = 7.1196, τˆ2 = 0.0055. The degrees-of-freedom parameter
was estimated to be νˆ = 3.7065. This indicates that the outlier effect is non-negligible
and αˆ has the mean parameter interpretation.
A multivariate normal distribution assumption produces the same decisions with regards
the hypothesis tested above. The only difference is on the relationship between gender
and kidney function. A multivariate normal distribution indicates that the relationship
is insignificant, p-value = 0.1174. There are differences in terms of the parameter esti-
mates. For example, whilst the multivariate normal model indicates that the patients
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who experienced stage 1 AKI had a loss of kidney function at a rate of 45.6% at the
acceleration period, multivariate t model indicates it was 35.8%. As an another exam-
ple, whilst the multivariate normal model indicates a recovery of a rate of 253.7% for
the patients with stage 2 or 3 AKI, multivariate t model indicates recovery of 74.9%.
Also, the standard error estimates of the fixed effects are inexorably smaller under the
multivariate t model.
4.4.2 Patient-specific results
The inferences we have presented so far are population-averaged. Our model allows us to
obtain patient-specific inferences as well. For example, predictions for eight patients are
displayed in Figures 4.2 and 4.3. Here, we shall note that these patients are deliberately
selected as the ones who reflect deviations from the population-averaged behaviours.
Point predictions and point-wise prediction intervals for the multivariate t model are
calculated as the mean and 2.5 and 97.5% quantiles of [Yij |Xij , αˆ, U˜i, W˜i(tij), τˆ2, γˆi] =
N(Xijαˆ + U˜i + W˜i(tij), τˆ
2/γˆi), where whilst γˆi is the mean of (4.14), U˜i and W˜i(tij)
are the means of the conditional distributions [Ui|Y i;θ] and [Wi(tij)|Y i;θ], based on
(4.16). These are obtained for the multivariate normal model by setting γˆi = 1. The
predictions for log-transformed eGFR measurements seem to be successful, as the noise
in the data are smoothed out and almost all the observations are included within the 95%
prediction intervals. The patients exhibit different behaviours in the pre-acceleration,
acceleration, recovery and post-recovery periods. For example, the patient with ID=46
has a longer recovery period, approximately 2 years, as opposed to the population-
averaged behaviours presented before. The patient with ID=187 has a sharp recovery
after which the level and rate of loss of kidney function are similar to these of the pre-
AKI period. The difference between the point predictions of the multivariate t (straight
lines) and multivariate normal (dashed lines) models are almost indiscernible. However,
in most cases the point-wise prediction intervals of the former are narrower. There are a
few observations that are covered by the prediction intervals of the multivariate normal
model, e.g. patients with ID=474 and 1220, but not these of the multivariate t model.
An explanation for this is that these observations are treated as outlying observations
by the latter model.
4.5 Diagnostics
To check the appropriateness of the model assumptions, diagnostic tests are applied to
standardised empirical residuals, ri
∗ = Si−1ri, where ri = Y i −Xiαˆ are the empirical





























































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Figure 4.5: Fitted values vs. standardised residuals. The dashed line is the zero line
(x-axis). The solid line is the LOWESS curve.
residuals, and SiSi






Fitted values, Xijαˆ, are plotted against the standardised residuals in Figure 4.5, where
dashed line denotes the LOWESS curve obtained by the R function lowess with the
default value for the smoothing parameter. There is no discernible systematic pattern
in the standardised residuals and no evidence of non-constant variance, and the fitted
LOWESS curve is close to 0.
We inspect the appropriateness of the assumed covariance structure through the vari-
ance structure of the standardised residuals. For a well-fitting model they are expected
to fluctuate around the theoretical variance of t(3.7065), 2.1720. The empirical and
theoretical variances are displayed in Figure 4.6. The empirical variances are calcu-
lated from binned residuals through time, with bin size of two weeks, but with baseline
data treated separately, that is, variances are calculated separately at baseline and over
follow-up measurements between 0+ and 14 days after baseline. Bins with fewer than
30 elements are omitted. Empirical variances of the standardised residuals randomly
fluctuate around 2.1720, which indicates the appropriateness of the assumed covariance
structure.
To further check the appropriateness of the assumed covariance structure, we use the
variogram of the standardised residuals (Diggle et al., 2002). The theoretical variogram
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Figure 4.6: Empirical variances of the standardised residuals through time. The
dashed line is the theoretical variance of the t distribution, 2.1720. Residuals are
binned through time with bin size of two weeks. Baseline data are treated separately.
Bins with fewer than 30 residuals are omitted.




ij − r∗ik)2, where uijk = |tij − tik|. Empirical




ij − r∗ik)2. For a well-fitting model, the empirical
variogram of the standardised residuals should randomly fluctuate around the variance
of t(3.7065), through u∗ijk = |t∗ij − t∗ik|, where t∗i. belongs to the vector of t∗i = Si−1ti
(Fitzmaurice, Laird and Ware, 2011). Since the observations are completely irregularly
spaced in the CRISIS data set, we average gijk over successive bins with equal and
pre-specified lengths through u∗ijk. We specifically consider the bins have a length of
two weeks, and omit the bins with fewer than 30 residuals. Variograms are displayed
in Figure 4.7. Here, the dashed line at height 2.1720 denotes the variance of t(3.7065).
The variograms fluctuate around 2.1720, which is consistent with the assumed covariance
structure.
The distributional assumption is checked by comparing theoretical and empirical quan-
tiles. The quantile-quantile plot for the multivariate normal model as well as the multi-
variate t model are plotted in left and right panels of Figure 4.8, respectively. We can
say that the multivariate t distribution is an appropriate choice for the CRISIS data set.
There are some discrepancies in the variogram, between lag 0-1.5 and 4.5-6, and the
quantile-quantile plot for the multivariate t model, towards the tails. Simulated reali-
sations for the variogram and quantile-quantile plot under the fitted model (not shown


















Figure 4.7: Empirical variogram based on the standardised residuals against the lag
based on the transformed time-scale. The variogram ordinates are averaged over bins
with width 14 days. Bins with fewer than 30 residuals are omitted. The dashed line at
2.1720 is the theoretical variogram of the standardised residuals under t(3.7065).
here) collectively suggest that the discrepancies can well be explained by randomness.
4.6 Simulation assessment
We conduct a simulation study to inspect the finite-sample behaviours of the estimators.
Data are generated under the multivariate t model, with κ = 0.5. Explanatory variables
of the CRISIS data are kept same, i.e. there are 2,289 patients with 38,829 repeated mea-
surements, 15 explanatory variables, etc. Only the random components of the model are
simulated. Parameters are set to those estimated based on the analysis of CRISIS data
set (Table 4.4). The simulated data sets are then analysed by the multivariate normal
and t models. Means of the parameter estimates, percentage biases, standard deviations
of the parameter estimates, means of the asymptotic standard error estimates, and the
coverage probabilities at 95% confidence level, based on 1,000 simulation replications,
are reported in Table 4.5.
Fixed effects parameter estimates for both the multivariate normal and t models are es-
sentially unbiased. Within each of these models, standard deviations of the fixed effects
parameter estimates and the means of the asymptotic standard errors are close to each
other. Also, for both of these models, coverage probabilities are close to the nominal








































































































































Figure 4.8: Quantile-quantile plot based on the standardised residuals under multi-
variate Normal (left panel) and multivariate t (right panel) models. Straight line on
each plot is the line of equality (y = x).
rate of 95%. The only difference between these models in terms of estimating the fixed
effects parameters is in the magnitude of the standard errors: the standard deviations
of the parameter estimates, as well as the means of the asymptotic standard error esti-
mates, are inexorably smaller for the multivariate t model. This feature is also observed
in the analysis of the CRISIS data set. Estimates of the random effects parameters and
degrees-of-freedom are essentially unbiased under the multivariate t model, and standard
deviations and the means of the asymptotic standard errors are close to each other for
these parameters. Whilst the coverage probabilities are close to the nominal rate for ω2,
τ2 and ν, they are sightly lower than the nominal rate for σ2 and φ; 91.0% and 91.2%
for the latter parameters, respectively. Here, we shall note that the standard error esti-
mates for these parameters are obtained numerically by central difference approximation
to the Hessian matrix. Although the random effects parameter estimates are essentially
unbiased under the multivariate normal model, standard errors of the parameter es-
timates are much larger than the means of the asymptotic standard error estimates.
Moreover, coverage probabilities for these parameters are much lower than the nominal
rate. Here, we shall note that true values of ω2, σ2 and τ2 for multivariate normal
model are considered to be 0.2770 (= 0.1275∗ 3.70653.7065−2), 0.2882 (= 0.1327∗ 3.70653.7065−2), and
0.0119 (= 0.0055∗ 3.70653.7065−2), respectively, since these values are the underlying variances
of the random effects.
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4.7 Discussion
In this study, we have investigated the influences of AKI on long-term kidney function
using longitudinal statistical modelling. The serial dependence is specified flexibly by
the Mate´rn correlation family. A robust distribution, specifically multivariate t distribu-
tion, is considered as the distribution of the random components of the model. Normal-
gamma hierarchical representation of the distribution helps us to easily apply the E-M
algorithm. We specify robust distributions for the random components, since diagnos-
tics based on the multivariate normal model indicated a bad fit. Possible explanations
for outlying observations in the CRISIS data set are low eGFR values in the recovery
period, high eGFR values in the same period due to very quick recovery, abrupt losses in
kidney function that occur more than seven days apart, e.g. non-acute renal problems,
or simply mistakes in data-entry. We considered three change-points in the longitudinal
trajectories of the patients who experienced AKI events. The change-points were iden-
tified by exploratory methods. We mainly have found that occurrence of AKI events
are preceded by significant accelerations in the kidney function losses. The patients had
quick recovery after having the AKI events. After the recovery-period, they started to
lose kidney function with a greater magnitude compared to the pre-acceleration period.
Overall, we can say that occurrence of AKI might have serious impact on long-term
kidney function.
The results in this study are based on observational data. Clinical trials would be needed
to have more reliable results. We considered two of the change-points are shared across
patients within AKI stages, then found these by exploratory methods. A better method
would be profile likelihood based on the multivariate t model. When the interest is
on individual change-points Bayesian methods would be more preferable, but when the
interest is on shared change-points, there is little to choose between Bayesian methods
and profile likelihood (Hall et al., 2003). In this study, we only considered longitudinal
modelling and ignored the influence of survival data. For example, in the CRISIS data
set, 305 (13.3%) of the patients had second AKI, 64 (2.8%) died due to renal related
reasons, 441 (19.3%) died due to other reasons, 1,479 (64.6%) were administratively
censored. Here, death due to renal reasons implies potentially informative drop-out. To
test this empirically, we fitted the multivariate t model to the CRISIS data set without
the patients whose reason for death is renal related. However, we observed that the
resulting estimates and standard errors are not considerably different than the ones
presented in the current paper. Potential future work is the incorporation of survival
information to the model presented in this study, as competing risks. Also, we only
investigated the influences of the first AKI events. The influence of multiple AKI events
Acute kidney injury amongst chronic kidney disease patients 94
can also be investigated. Risk of having AKI events might be explored possibly with
joint modelling of longitudinal eGFR measurements and time to recurrent AKI events.
4.8 Supplementary material: R codes
# R codes for parameter estimation and prediction of the random effects
# loading the package, version 1.1
R> library(lmenssp)
# reading the data set into R
R> crisis.data <- read.csv("crisis.censor2.omit.txt", header = T)
# formula to be used parameter estimation and smoothing
# for the explanations of the variables see Table 4.4
R> formula = log.eGFR ~ fu + pwl1.stage1 + pwl3.stage1 + pwl4.stage1 +
+ pwl2.stage23 + pwl3.stage23 + pwl5.stage23 +
+ age.0 + salford + male + smoking +
+ alcohol + diabetes + mcp
# obtaining the parameter estimates
R> fit.heavy.exp <- lmenssp.heavy(formula = formula, data = crisis.data,
+ id = crisis.data$id,
+ process = "sgp-matern-0.5",
+ timeVar = crisis.data$fu, init.em = 5,
+ tol.em = 1e-5, maxiter.em = 1000,
+ silent = FALSE)
R> fit.heavy.exp
# obtaining the predictive distributions of [U_i|Y_i],
# [W_i(t_{ik})|Y_i], for patient with ID = 1
R> smooth <- smoothed.heavy(formula = formula, data = crisis.data,
+ id = crisis.data$id, process = "sgp-matern-0.5",
+ timeVar = crisis.data$fu,
+ estimate = fit.heavy.exp$estimate, subj.id = 1)
R> smooth
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Appendix: Sensitivity analysis on patients with no AKI
In the previous analyses, presented in Chapter 4.4, we assumed that the data for the
patients with no AKI events (1,576 of them) were all on the pre-acceleration period.
Nonetheless, for these patients, some portion of the data from the end might fall into
the acceleration period. Ignoring this might add biases to the parameter estimates, e.g.
population-averaged slope estimates. To inspect this, we conduct a sensitivity analysis,
in which we exclude some amount of data from the end of data recording, i.e. data points
falling into [tni − e, tni ], for the patients with no AKI events. We specifically considered
e = 0.04 years (≈ 15 days), 0.08 years (≈ 30 days), 0.12 years (≈ 45 days), and 0.16 years
(≈ 60 days). If a patient has a total follow-up time less than these values, i.e. tni ≤ e, we
only keep the baseline data for that patient. Respective number of observations excluded
for the above values of e are 1,801 (4.6%), 2,024 (5.2%), 2,215 (5.7%), 2,429 (6.3%), out
of 38,829 repeated measurements. We then re-analyse these data sets by the multivariate
normal and t models. Results based on the multivariate t model are presented in Tables
4.6 and 4.7. There are negligible changes in the parameter estimates compared to the
results presented in Table 4.4. Results based on the multivariate normal model are not
reported here, since the changes are based on this model are also negligible.
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Chapter 5
lmenssp: an R package for linear
mixed effects models with
non-stationary stochastic
processes
This chapter is based on the following paper:
Asar O¨. and Diggle P. J. (2014). lmenssp: An R Package for Linear Mixed Effects
Models with Non-stationary Stochastic Processes. Submitted to Journal of Statistical
Software.
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Abstract
Linear mixed models are widely used for analysis of repeated measurement data. The
classical random-intercept-and-slope model is useful for datasets with short follow-up
times. Models based on stationary Gaussian processes are more useful for data-sets
with long follow-up times, but the stationarity assumption is too restrictive for univer-
sal application. Models based on non-stationary Gaussian processes have been proposed
in the literature, but are not implemented in widely available software. In this pa-
per, we introduce the R package lmenssp for linear mixed models whose random effect
component includes a continuous-time non-stationary ergodic component. Three such
processes are considered: 1) Brownian motion, 2) integrated Brownian motion, and 3)
integrated Ornstein-Uhlenbeck process. Core features of lmenssp are illustrated using
a simulated data set.
Key words: Filtering, forecasting, maximum likelihood estimation, random effects,
smoothing
5.1 Introduction
Gaussian linear mixed effects models are widely used for analysis of repeated measure-
ment data. Two examples are the random-intercept-and-slope, or Laird-Ware model
(Laird and Ware, 1982) and various stationary Gaussian process models; see, for exam-
ple, Diggle (1988). Both of these model classes can be fitted in readily available software,
including R (R Development Core Team, 2014) packages, e.g., the nlme package (Pinheiro
et al., 2014).
In the Laird-Ware model, the random effect component for subject i at time t is Ui+Vit.
The subject-specific variation in the response variable at study entry is captured by
random intercepts, Ui, whilst subsequent subject-specific variation in the longitudinal
trajectories over time is captured by the random slopes, Vi. Here, Vi is time-independent,
and postulates that each subject has his/her own slope, but these slopes are straight lines.
In the stationary Gaussian process model, the random effect component is Ui + Si(t),
where the Ui are as before and the Si(t) are independent copies of a stationary Gaussian
process whose correlation function ρ(u) is typically specified to lie within one of a small
number of standard families, for example the exponential, ρ(u) = exp(−u/φ), the so-
called Gaussian, ρ(u) = exp
(−(u/φ)2), or the more general Mate´rn family (Mate´rn,
1960) that includes the exponential and Gaussian as special cases. Now the random
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slopes, Si(t), depend on time, hence the straight line assumption of the Laird-Ware
model is relaxed.
The Laird-Ware model is useful for data sets with short sequences of repeated measure-
ments, but is usually too inflexible to capture the covariance structure of data sets with
long follow-up times. Continuous-time ergodic Gaussian processes are more suitable for
data sets with long follow-up times, but the stationarity assumption is too restrictive for
universal application. Several authors have proposed non-stationary models, including
Taylor, Cumberland and Sy (1994), Taylor and Law (1998), and Diggle, Sousa and Asar
(2014).
Models whose random effect component includes a stationary stochastic process can be
fitted in R using the nlme package. However, mixed models with continuous-time non-
stationary ergodic components are not available in R. In this paper, we introduce the
R package lmenssp that fits mixed models whose random effect component can include
any one of the following continuous-time non-stationary ergodic processes: 1) Brownian
motion; 2) integrated Brownian motion; 3) integrated Ornstein-Uhlenbeck process.
The paper is organised as follows. In Section 5.2, we give details of the modelling
framework. In Section 5.3, we discuss the core features of the lmenssp package. Section
5.4 gives examples of its use, and the paper ends with a brief discussion in Section 5.5.
5.2 Modelling framework
The model we consider is of the form
Yij = Xijα+ Ui +Wi(tij) + Zij . (5.1)
Here, Yij is the jth (j = 1, . . . , ni) response of the ith (i = 1, . . . ,m) subject at the
time point tij . Xij is an associated vector of p + 1 covariates (including intercept)
and α is the corresponding vector of fixed effects regression parameters. The Ui are
random intercepts, assumed to be independent N(0, ω2) random variables. The Wi(tij)
are continuous-time non-stationary stochastic process, the details of which are discussed
below. Finally, the Zij are mutually independent N(0, τ
2) random error terms.
We consider three specifications for W (t). The first is Brownian motion (BM) for which
the marginal distribution is
[W (t)] = N(0, σ2t), (5.2)
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where we use [·] to mean “the distribution of”. The covariance function of the process is
Cov (W (s),W (t)) = σ2min(s, t). (5.3)





where B(t) is now Brownian motion. The marginal distribution and covariance function
of IBM are
















The cross-covariance between IBM and its related BM is
Cov(B(s),W (t)) = σ2
t2
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, if s < t. (5.7)





where B(t) is now an Ornstein-Uhlenbeck (OU) process. The OU process has the fol-













respectively. These in turn yield the following marginal distribution and covariance
structure for IOU,
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and




2νmin(s, t) + e−νt + e−νs − 1− e−ν|t−s|
)
, (5.12)
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2− e−νs − eν(s−t)
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, if s < t. (5.13)
Note that BM can be obtained as a limiting case of IOU when κ2/ν2 is constant and
ν →∞.
For the details of these stochastic processes, we refer the interested reader to Taylor,
Cumberland and Sy (1994); Taylor and Law (1998); Ross (1996); Robinson (2010);
Diggle, Sousa and Asar (2014).
The distributional properties of Ui, Wi(tij) (either specified as BM, IBM or IOU) and
Zij induce a multivariate normal distribution for Yi = (Yi1, . . . , Yini)
T ,
[Yi] = MVN(Xiα, Vi(φ)),
where Xi = (X
T
i1, . . . , X
T
ini
)T , α is as before, and
Vi(φ) = ω






for BM and IBM and φ =
{
ω2, κ2, ν, τ2
}
for IOU. Ji is an
ni × ni matrix of ones, Ri is an ni × ni matrix structured by Cov(W(s), W(t)) de-
pending on the specification of W (t), and Ii is an ni × ni identity matrix. We es-
timate the parameters, θ = {αT , φ}, by maximum likelihood (ML) estimation with
a Fisher-Scoring (FS) algorithm as described in Jennrich and Schluchter (1986) and
Diggle, Sousa and Asar (2014). Convergence is assessed by the following criterion:√
{φm − φm+1}{φm − φm+1}T < tolerance, where m and m + 1 denote successive FS
steps.
The following conditional distributions are of interest: [Ui|Yi; θ], [Wi(tik)|Y ki ; θ], [Wi(tik)|Yi; θ],
[Bi(tik)|Y ki ; θ] and [Bi(tik)|Yi; θ], where Y ki = (Yi1, . . . , Yik)T . The second and fourth of
these are needed for filtering, the third and fifth for smoothing and forecasting of the
stochastic processes in the sense of Durbin and Koopman (2012). The general forms of
these distributions are obtained from multivariate Normal theory (Anderson, 1984) as
follows:




i (Yi −Xiα), ω2 −KTi V −1i Ki
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, (5.15)
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−1 (Yi −Xiα) ,Var (Wi(tik))− FiTVi−1Fi
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, (5.17)
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and, for the IBM and IOU processes,



















−1 (Yi −Xiα) ,Var (Bi(tik))− LiTVi−1Li
)
. (5.19)
Here, Ki = ω
21i, where 1i is an ni×1 matrix and V ki is the variance-covariance matrix of
Y ki . F
k
i and Fi are structured by Cov(W (s),W (t)), and L
k
i and Li by Cov(B(s),W (t)),
depending on the specification of B(t) and W (t).
5.3 The package lmenssp
The function lmenssp obtains the ML estimates of θ. The default version of the function
has the following form:
R> lmenssp(formula, data = NULL, id, process = "bm", timeVar, init = NULL,
+ tol = 1e-5, maxiter = 100, silent = TRUE)
Here, formula is a standard R formula for fixed effects component of the model. data
is a data frame from which the variables are to be extracted. id is a vector for subject
identification. process is a character string for the stochastic process, where "bm",
"ibm" and "iou" correspond to BM, IBM and IOU, respectively. "timeVar" is a vector
for the time variable. "init" is a vector of initial values to start the FS algorithm. If
the user does not provide their own values, lmenssp obtains these by fitting a random
intercept and random slope model, using the lme function of the nlme package. tol
is the maximum tolerance value to assess the convergence. maxiter is the maximum
number of iterations for the FS algorithm. silent is a logical variable; if set to FALSE
the details of the FS steps are to be printed whilst the algorithm is running.
The distributions (5.16) and (5.18) are obtained by the function filtered, the distri-
butions (5.17) and (5.19) by the function smoothed. In each case, estimated parameter
values are used for plug-in prediction. The default forms of these functions are given
below:
R> filtered(formula, data = NULL, id, process = "bm", timeVar,
estimate, subj.id)
R> smoothed(formula, data = NULL, id, process = "bm", timeVar,
estimate, subj.id = NULL, fine = NULL, eq.forec = NULL,
uneq.forec = NULL)
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The explanations for formula, data, id, process and timeVar are the same as those
for the function lmenssp. estimate is a vector for the ML estimates produced by
the lmenssp function. subj.id is a vector for the IDs of the subjects for whom the
aforementioned distributions are to obtained. fine is a numerical value for smoothing
at fine intervals within the follow-up period. eq.forec is a two-element vector for
forecasting at equally spaced time intervals, where whilst the first element corresponds
to the forecast time interval, the second element corresponds to the number of forecasts.
uneq.forec is a two-column data frame or matrix for forecasting at unequally spaced
time intervals, where the first column includes the IDs, the second column includes the
forecast time intervals.
lmenssp, filtered and smoothed return their results as lists as described in Section
5.4.
5.4 Examples
The package includes a longitudinal data set, data.sim.ibm. The data set was simulated
under a mixed effects model with IBM as the stochastic component. It includes data
for 500 subjects with total of 8,462 repeated measurements. There are 6 variables: 1)
id: identification number of the subjects, 2) sex: sex of the subjects taking 0 for male,
1 for female, 3) bage: baseline age in years, 4) fu: follow-up time in years, 5) pwl:
piecewise linear term, calculated as max(0, age at measurement − 56.5), 6) log.egfr:
the response variable, representing the logarithm of estimated glomerular filtration rate.
For the details of these variables and the methods for data simulation, see diggle14.
The ML estimates of the parameters based on the mixed model with IBM as the process
can be obtained by the following script:
R> library("lmenssp")
R> data("data.sim.ibm")
R> formula <- log.egfr ~ sex + bage + fu + pwl
R> fit.ibm <- lmenssp(formula = formula, data = data.sim.ibm,
+ id = data.sim.ibm$id, process = "ibm", timeVar = data.sim.ibm$fu,
+ silent = FALSE)
The related output includes a list of results which can be printed by
R> fit.ibm
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$title
[1] "Mixed effects model with random intercept and integrated Brownian motion"
$date
[1] "Tue Oct 21 19:34:19 2014"
$estimates
Estimate Standard error Z-estimate p-value
Intercept 4.432030443 0.1468746545 30.1755974 0.0000000000
sex -0.110998143 0.0336960921 -3.2940954 0.0009873897
bage -0.001063977 0.0028473161 -0.3736773 0.7086444131
fu -0.009685761 0.0078669187 -1.2312014 0.2182475462
pwl -0.012347446 0.0039634284 -3.1153447 0.0018373009
omegasq 0.118806815 0.0084673249 NA NA
sigmasq 0.017784990 0.0012323705 NA NA





[1,] -0.008013553 -0.6852443 0.2547693
In the output, maxloglik is the value of the maximised log-likelihood, and score gives
the values of the gradient (first partial derivatives of the log-likelihood function), evalu-
ated at the ML estimates of the parameters.
Filtering and smoothing distributions for the subjects, e.g., the ones with ID=1 and 2,
can be obtained by the following scripts:
R> subj.id <- c(1, 2)
R> fil.res <- filtered(formula = formula, data = data.sim.ibm,
+ id = data.sim.ibm$id, process = "ibm", timeVar = data.sim.ibm$fu,
+ estimate = fit.ibm$estimate[, 1], subj.id = subj.id)
R> smo.res <- smoothed(formula = formula, data = data.sim.ibm,
+ id = data.sim.ibm$id, process = "ibm", timeVar = data.sim.ibm$fu,
+ estimate = fit.ibm$estimate[, 1], subj.id = subj.id)
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[1] "Filtering for the mixed model with integrated Brownian motion"
$date
[1] "Tue Oct 21 19:37:19 2014"
$u
id mean variance
[1,] 1 0.03032635 0.011268446
[2,] 2 -0.27005285 0.005422657
$w
id time mean variance
[1,] 1 0.00000000 0.000000e+00 0.000000e+00
[2,] 1 0.15331964 -1.098346e-04 2.136091e-05
[3,] 1 0.68993840 1.052777e-02 1.898799e-03
...
[16,] 2 0.00000000 0.000000e+00 0.000000e+00
[17,] 2 0.03011636 1.960017e-07 1.619343e-07
[18,] 2 0.03559206 6.810425e-07 2.672946e-07
...
$b
id time mean variance
[1,] 1 0.00000000 0.000000e+00 0.0000000000
[2,] 1 0.15331964 -1.074565e-03 0.0027262892
[3,] 1 0.68993840 2.350504e-02 0.0120395202
...
[16,] 2 0.00000000 0.000000e+00 0.0000000000
[17,] 2 0.03011636 9.762222e-06 0.0005356184
[18,] 2 0.03559206 2.855346e-05 0.0006330028
...
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In the output, mean and variance are the mean and variance of the corresponding
distribution.
Smoothing also can be carried out at time points within the follow-up period at which
measurements were not taken. For example, for subjects with ID=1 and 2, smoothing
at fine intervals of 0.01 years are obtained by
R> smo.within <- smoothed(formula = formula, data = data.sim.ibm,
+ id = data.sim.ibm$id, process = "ibm", timeVar = data.sim.ibm$fu,
+ estimate = fit.ibm$estimate[, 1], subj.id = subj.id, fine = 0.01)
On the other hand, forecasting with lead time u, i.e. at tini +u can be carried out using
the smoothed function. This might be done either at equally spaced intervals with the
same number of forecasts for each subject by using the eq.forec option, or at unequally
spaced intervals with equal or varying number of forecasts for different subjects by using
the uneq.forec option. For example, whilst one, two and three month ahead forecasts
for the subjects with ID=1 and 2 are obtained by
R> eq.forecast <- smoothed(formula = formula, data = data.sim.ibm,
+ id = data.sim.ibm$id, process = "ibm", timeVar = data.sim.ibm$fu,
+ estimate = fit.ibm$estimate[, 1], subj.id = subj.id,
+ eq.forec = c(1/12, 3))
one, two and six month ahead forecasts for the subject with ID=1 and one and three
month ahead forecasts for the subject with ID=2 are obtained by
R> uneq.forec <- data.frame(c(1, 1, 1, 2, 2), c(1/12, 2/12, 6/12, 1/12, 3/12))
R> uneq.forecast <- smoothed(formula = formula, data = data.sim.ibm,
+ id = data.sim.ibm$id, process = "ibm", timeVar = data.sim.ibm$fu,
+ estimate = fit.ibm$estimate[, 1], uneq.forec = uneq.forec)
Filtering and smoothing (as well as forecasting) for new subjects whose data are not
included in estimation of the model parameters can also be carried out. For example for
a new (hypothetical) subject, filtering is carried out by the following scripts
R> data.501 <- data.frame(id = c(501, 501, 501), sex = c(0, 0, 0),
+ bage = c(50, 50, 50), fu = c(0, 0.2, 0.4),
+ pwl = c(0, 0, 0), log.egfr = c(4.3, 2.1, 4.1))
R> fil.501 <- filtered(formula = formula, data = data.501,
+ id = data.501$id, process = "ibm", timeVar = data.501$fu,
+ estimate = fit.ibm$estimate[, 1], subj.id = 501)
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5.5 Discussion
In this paper, we introduced the R package lmenssp for linear mixed effects models
with three different structures for a non-stationary stochastic component, BM, IBM and
IOU. The package includes three main functions: lmenssp for ML estimates of the model
parameters; filtered for filtering, smoothed for smoothing. Filtering and smoothing
are carried out for the current level of the stochastic process, W (t), as well as the rate
of change, B(t), since they are both of scientific interest in some studies, e.g. see Diggle,
Sousa and Asar (2014). The function variogram in lmenssp, which is not discussed
in the current paper, but illustrated in the package manual, can be used to calculate
the empirical variogram, which is a useful tool for deciding the use of non-stationary
stochastic processes, e.g., when the variogram does not level-off (Diggle et al., 2002).
A potential extension is to replace random intercept Ui in (5.1) by a random effect Dijbi
where Dij is typically a subset of Xij and bi is a corresponding vector of random effects,
assumed to follow a zero-mean multivariate Normal distribution.
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In this thesis we developed statistical methods and associated software that are mo-
tivated by public health renal problems. Additionally, we did a case study on renal
medicine which we presented as an educational material that aims at both statisticians
and non-statisticians.
In Chapter 2, we presented the educational material on joint analysis of longitudinal and
survival data. Methods were illustrated on a longitudinal data set on chronic kidney
disease patients. Such a study is important in terms of encouraging the use of new
statistical methods amongst practitioners of statistics.
In Chapter 3, we offered a probabilistic solution to a prediction problem concerning
referral of primary care patients to secondary care. The methods consider the following
clinical criterion: patients losing kidney function at least at a relative rate of 5% should
be referred to secondary care. We considered a large data set which belongs to patients
who were flagged as having pre-disposing conditions for renal failure. This is an im-
portant study, since if the patients can be appropriately referred to secondary care, the
time to serious renal problems, e.g. renal failure, and the need for serious treatments,
e.g. renal replacement therapy, might be postponed.
In Chapter 4, we investigated the influence of AKI on long-term kidney health amongst
chronic kidney disease patients. AKI is a medically well studied phenomenon, but its
influence on kidney function is still unknown. We considered data-driven statistical
methods to inspect the influence. The model is a linear mixed effects model with a
stationary stochastic process based on multivariate t-distributed repeated measures.
This is an important study, since understanding the impact of it might lead doctors
to take necessary precautions to prevent its recurrence and other related complications.
In Chapter 5, we developed the R package lmenssp (version 1.0) to estimate the model
parameters for mixed effects models with non-stationary stochastic process components.
Predictions based on filtering and smoothing distributions and forecasting are also con-
sidered. The core features of the package are illustrated by a simulated data set that is
similar to the primary care data set used in Chapter 3. We have added to lmenssp in
the version 1.1 parameter estimation, prediction and forecasting for mixed models with
stationary processes, and mixed models with stationary and non-stationary process with
a multivariate t distribution.
The methods that are developed in Chapter 3 and 4 ignore the survival information. A
natural extension of the methods presented in these chapters is joint modelling, which
is on-going. Inference for joint models with stochastic processes is computationally
cumbersome because of the high-dimensional integrals in the E-steps when the E-M
scheme is opted for parameter estimation, and the requirement of the continuous path
General discussion and future works 116
of the stochastic processes in the survivor function integral. Monte-Carlo methods are
typically needed to approximately solve the former integrals. The latter is not a problem
when the baseline hazard is left unspecified, since the value of the process is only needed
at the event times. However, some form of approximation, e.g. discretisation, is needed
for parametric baseline hazard options. Similarly, we assumed in these studies that the
follow-up time is non-informative. This might not be true for observational studies,
since the timing of the follow-up times are not pre-specified and might depend on the
underlying kidney function. We are currently working on an extension of these methods
to informative follow-up times with a joint modelling approach for simultaneous analysis
of the observation and follow-up processes (Ryu et al., 2007; Diggle et al., 2010). To
convey our message in Chapter 3 to physicians, a more detailed case-study on a more up-
to-date data is needed. We are currently working on such a project. We aim to develop a
real-time surveillance system to be used by general practitioners as a result of this study.
In Chapter 4, we detected AKI events retrospectively based on SCr measurements using
a clinical guideline. Observed SCr data are noisy and might add uncertainty to the
AKI detection. However, under the current circumstances, this is the best we can do,
since ‘real’ AKI events are typically unrecorded. In most of the cases only the primary
disease that drives AKI are recorded, and the rough record rate of AKI events is one in
three. Currently, we have been checking the correctness of the AKI events we detected
and the underlying causes of these events, through the paper records of the SRFT. In
the same chapter, we only investigated the influences of the first AKI events on kidney
function. Future work regarding the influnce of AKI on long-term kidney function is
the incorporation of these new features together with the underlying cause of CKD to
our analyses. In addition to these studies, which are related to renal medicine, we have
started working on a new project on osteoarthritis. Our aim in this study is to develop
spectral analysis methods for replicated non-stationary high-frequency time series data
(Diggle and Al Wasel, 1997). Two projects on mental health randomised clinical trials
are also other on-going projects of ours.
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